What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2024-02-22 compared with 2023-02-21 · 449 added, 560 removed, 395 unchanged (72% of the section changed)

Quest Diagnostics Incorporated is the world's leading provider of diagnostic information services.

We play a crucial role in the healthcare ecosystem, empowering people to take action to improve health outcomes.

Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management.

In the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.

Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time.

We provide diagnostic insights from the results of our laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes.

Derived from one of the world's largest databases of de-identifiable clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management.

In the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world.

The patients we serve annually comprise approximately one-third of the adult population of the United States, and over a three-year period, we serve approximately one-half of the adult population in the United States.

We estimate that annually we serve approximately half of the physicians and half of the hospitals in the United States.

The Quest Way

We operate our business and achieve our goals according to a clear set of principles we call “The Quest Way,” which consists of the following:

• Our Purpose is to work together to create a healthier world, one life at a time.

• Our Strategy to grow is to provide solutions that serve the evolving needs of our customers, based on our high quality, innovative, convenient and affordable services.

• Our Culture, or how we work, is powered by what we call the “5Cs”:

customer first, collaboration, care, continuous improvement, and curiosity.

We play a critical role in healthcare decisions for customers across the healthcare ecosystem, including physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers.

We believe The Quest Way is aligned with the triple aim of healthcare of improving medical quality and the patient experience while reducing the overall cost of care.

We believe our employees are critical to our success, and we continually strive to create an environment that allows them to contribute to our goal of creating a healthier world.

We are focused on delivering services that help improve the physician and healthcare provider experience to enable us and them to deliver high quality, effective and affordable care to patients.

We provide a number of innovative ways for patients to access services from us, including consumer-initiated services offered through QuestHealth.com, which provides a high quality, self-directed option with physician oversight for individuals to gain insights into their health.

During 2023, we generated net revenues of $9.3 billion.

Additional financial information concerning Quest Diagnostics for each of the years ended December 31, 2023, 2022 and 2021 is included in “Management's Discussion and Analysis of Financial Condition and Results of Operations” in Part II, It em 7 and our consolidated financial statements and notes thereto in “Financial Statements and Supplementary Data” in Part II, Item 8.

Quest Diagnostics was incorporated in Delaware in 1990;

1 unchanged sentence

We conduct business through our headquarters in Secaucus, New Jersey, and our laboratories, patient service centers, offices and other facilities around the United States and in selected locations outside the United States.

Unless the context otherwise requires, the terms “Quest Diagnostics,” the “Company,” “we” and “our” mean Quest Diagnostics Incorporated and its consolidated subsidiaries.

The patients we serve comprise approximately one-third of the adult population of the United States annually, and approximately one-half of the adult population in the United States over a three-year period.

We estimate that annually we serve approximately half of the physicians and half of the hospitals in the United States.

During 2022, we generated net revenues of $9.9 billion.

Additional financial information concerning Quest Diagnostics for each of the years ended December 31, 2022, 2021 and 2020 is included in the consolidated financial statements and notes thereto in “Financial Statements and Supplementary Data” in Part II, Item 8.

Our vision, aspirational goals and values are set forth below.

We believe that our vision, aspirational goals and strategy align very well with, and our strong value proposition supports, the triple aim of healthcare:

improving medical quality and the patient experience while reducing the cost of care.

Quest Diagnostics was at the forefront of the response to the COVID-19 pandemic, playing a pivotal role to broaden access to laboratory insights to help people lead healthier and safer lives.

We provided both molecular diagnostic and antibody serology tests to aid in the diagnosis of COVID-19 and the detection of immune response to the virus, and have performed approximately 77 million of these tests.

We built up and maintained the testing capacity to handle surges in COVID-19 testing demands, including using our national courier, air fleet and logistics network to balance volume across approximately two dozen COVID-19 testing laboratories, and also through our laboratory referral partner program.

We worked with federal, state and local governments, healthcare organizations, payers, suppliers, retailers, trade associations and other laboratories in the effort to bring as much COVID-19 testing as possible to the American people.

We also provided data on COVID-19 testing that we conducted to federal, state and local public health authorities, including the CDC, and participated in studies with government and private institutions, aiding COVID-19 public health response and research.

All of our employees, including our dedicated laboratory professionals, phlebotomists, air fleet team, and couriers took tremendous pride in the role we played and worked tirelessly to help patients and communities access quality COVID-19 testing.

As the impact of COVID-19 moderates, we remain active in the continued response to COVID-19, including supporting ongoing testing needs and public health response.

We also saw how underserved communities were disproportionately impacted by COVID-19, and with the Quest Diagnostics Foundation, we launched Quest for Health Equity, an initiative to reduce health disparities in underserved communities in the U.S.

This initiative is providing a combination of testing services, education programs, alliances and financial support to efforts to address health disparities.

Since its inception, we have committed approximately $30 million to approximately 65 programs launched across the U.S.

and Puerto Rico, including supporting COVID-19 testing and vaccination events, wellness events, educating young students on healthy nutrition choices and expanding research and mentorship opportunities for Black and Hispanic scholars.

Numerous Quest for Health Equity undertakings demonstrate our commitment to FQHCs and the people they serve, including by providing free lab testing services.

Our approach to fighting the COVID-19 pandemic was rooted in our vision of empowering better health through diagnostic insights.

We believe that the challenges we faced from the COVID-19 pandemic brought us together, made us a stronger company and will help us capture the substantial opportunities in front of us.

We have a two-point business strategy, reviewed by our Board of Directors, to achieve our vision and our goals.

Accelerate Growth

Our strategy to accelerate revenue growth is based on the Company’s portfolio of services.

Services Portfolio (Table 1)

Activity Key Characteristics At A Glance Quest Value Proposition

General Diagnostics Testing services generating strong cash flows and steady growth • Routine and non-routine testing services

• Largest revenue stream

• Essential portion of healthcare delivery

• Operational excellence

• Access and convenience

Advanced Diagnostics Testing services targeting faster growth through innovation testing model • Genetic and advanced molecular testing services

• An important part of precision medicine

• Innovation-based competitors

• Rich clinical, scientific and medical innovation expertise

• Quality and reliability of new assays

• Ability to manage potential new regulatory requirements

Diagnostic Services Laboratory and data-related healthcare opportunities targeting faster growth • Enables partners to deliver healthcare more efficiently ( e.g.

, risk assessment;

Professional Laboratory Services;

Employer Population Health)

• Services to support population health ( e.g.

, data analytics;

extended care services)

• Extensive diagnostic capability

• Large and growing database and analytics expertise

• Partnerships with industry leaders across healthcare landscape

We have identified the following five approaches to accelerate growth.

Approaches to Accelerate Growth (Table 2)

Delivering annual revenue growth of more than 2% through accretive, strategic acquisitions

Plus organic growth through:

Capitalizing on increased health plan access

Increasing share with IDNs

Growing Advanced Diagnostics

Building consumer-initiated testing

Growing through acquisitions.

We endeavor to grow revenue each year by more than 2% through accretive, strategic acquisitions (our target has been based on our revenues excluding the revenues from our COVID-19 testing).

Acquisition opportunities may include IDN outreach businesses, regional laboratory consolidation and businesses that will provide us with new capabilities.

Our approach to acquisitions, and the key acquisitions we consummated during 2022, are discussed below under the heading Deliver disciplined capital deployment .

Capitalizing on increased health plan access.

We are focused on opportunities to partner with health plans.

We strengthen our relationships with health plans and increase the volume of our services for their members by focusing on driving value and providing strong value propositions for members and clinicians.

This includes working with payers to reduce the cost of care, improve the customer experience and drive better outcomes for populations.

For example, we strive to build information platforms to help health plans manage utilization and population health, keep laboratory testing in network and provide an alternative to high-cost labs.

We also offer extended care services to help close gaps in care designed to be attractive to payers.

In 2022, we augmented our extended care offering by acquiring Pack Health, a patient engagement company that helps individuals adopt healthier behaviors to improve outcomes.

We expanded the plans with which we have a value-based

contracting relationship, fostering better alignment with the health plans.

We also renewed our longstanding strategic relationship with Blue Cross and Blue Shield of Florida, Inc.

Increasing share with IDNs.

We believe that the growing market challenges faced by IDNs, including continued consolidation, price transparency, cost and utilization pressure, evolving healthcare payment models, capital needs, changing technology and limited resources, provide us with an opportunity to partner with them more effectively as they consider their laboratory testing strategy and drive demand for our expertise.

We have deployed a dedicated team to strengthen our relationships with IDNs, including with respect to their reference testing.

We target three specific opportunities:

reference testing, outreach testing and lab management.

We provide reference testing for approximately half of the hospitals in the U.S.

and are a leading provider of this testing in the country.

Our industry-leading Professional Laboratory Services, highlighted in Table 3, provides a suite of solutions to help IDNs build and execute their laboratory strategy, improve quality, reduce the cost of care and focus on core competencies.

We purchase outreach testing businesses from IDNs that decide to exit that business.

In 2022, we continued to work with IDNs to help them execute their lab strategy, started providing laboratory management services to Lee Health, a community-owned health system in Southwest Florida, and entered an agreement to provide lab management services to Northern Light Health, a large integrated healthcare system in Maine.

In addition, as discussed below under the heading Deliver disciplined capital deployment, we acquired the outreach testing business of Summa Health, a large integrated healthcare system in Northeastern Ohio, and agreed to acquire select assets of Northern Light Health's outreach testing business.

We also were awarded a group purchasing agreement for our laboratory stewardship solution, including Quest Lab Stewardship TM Enterprise powered by hc1 ® , with Premier Inc., a leading healthcare improvement company uniting an alliance of hospitals, health systems and providers.

Key Professional Laboratory Services Offerings (Table 3)

Lab management outsourcing Advanced data solutions

Test menu optimization and spend consolidation Reference testing, including advanced diagnostics

Supply chain management and purchasing Blood utilization management

Growing Advanced Diagnostics.

We are a leading provider of Advanced Diagnostics, with an array of offerings across the spectrum.

We aim to accelerate the growth of our Advanced Diagnostics offerings to a growth rate of at least 8% per year.

We have been investing in our Advanced Diagnostics offerings, including to enhance our innovation capabilities and to strengthen our service offering and sales force, to make our Advanced Diagnostics offerings more attractive and accessible to IDNs and clinicians.

In addition, we have invested in reducing the cost of next-generation sequencing and combining that with the power of our Blueprint Genetics ® data analytics capabilities.

We are seeking to apply the capabilities gained by these efforts to other areas where we can make a meaningful difference in health care, including consumer genetics and offerings to pharmaceutical companies, IDNs and health plans.

In 2022, we invested in our bioinformatics capabilities and our women's health sales force, and to accelerate growth in oncology, hematology, and pharma services.

We introduced the Solid Tumor Expanded Panel to help oncologists with therapy selection and Quest AD Detect, a blood test to aid in the early assessment of Alzheimer's disease.

During 2022, we saw strong growth in prenatal genetic testing and pharma services.

Building consumer-initiated testing.

For many years, we have been focused on the consumer, and have taken strong steps to be recognized as the consumer-friendly provider of choice of diagnostic information services.

Our strong consumer focus is highlighted in Table 4.

We will continue to focus on improving the consumer experience, including through improved digitization and other enhancements of our operations.

For example, our "Schedule at Check In" capability, which encourages patients to make appointments, allowing us to better manage demand and phlebotomy productivity while enhancing the patient experience, is now deployed at approximately 85% of our patient service centers.

We have increased to approximately 80% the number of our patients coming to a patient service center who have appointments, and reduced average wait times in the centers.

We also are sending more messages to patients via SMS text, increasing the speed and utility of information flow to patients and patient satisfaction.

In addition, we are building the patient payment process into the digital customer experience, improving the patient experience, helping our patient concession rate, and reducing demands on phlebotomists.

Increasing consumer expectations inform our design for our consumer experience.

Consumer-Centric Initiatives (Table 4)

Connectivity and access to information • >27.5 million registered users in our MyQuest ® health portal and mobile connectivity solution, up over 6 million from a year ago.

• Quest lab results available for Android users through the CommonHealth app.

• MyQuest ® supports Health Records using the Apple Health app.

• Using MyQuest, ® consumers can manage healthcare for a group of individuals.

Reminders • Consumers whose physicians have ordered a test for them electronically can receive email reminders to complete the test.

• Consumers who have made appointments can receive appointment reminders via text messaging.

Enhanced experience • Electronic check-in at patient service centers.

• Improved on-line pre-registration and appointment scheduling.

• Real-time payment determination.

Convenient access • Partnerships with Walmart and Safeway to expand convenient access to testing services at select Walmart and Safeway locations across the United States (approximately 200 locations at year end).

Self-collection technology • Proprietary, consumer-friendly self-collection technology offered

Satisfaction • We are measuring consumer satisfaction.

In 2018, we launched our consumer-initiated testing offering that permits consumers to request their own lab tests, to allow consumers to take control of, and to better understand, their own health through access to personal diagnostic information.

In an evolving healthcare environment, consumers are increasingly engaged in their health care and want control, a dynamic experience and convenience.

Our QuestHealth TM offering reflects our belief that by building on the foundation of our strong consumer focus we can capture growing opportunities in consumer-initiated testing and demand for expanded access to basic health care services.

In 2022, we continued to invest in our offering, launching an enhanced digital platform with a more powerful and consumer-friendly user experience designed to better acquire, convert and retain more customers.

We collaborated with Walmart, to make consumer-initiated testing available through Walmart.com, and with eMed TM , to launch a COVID-19 rapid antigen test with observed collection, helping individuals meet travel and other observed collection and test report requirements.

We are focusing on consumer interest to experience health care in a different way

and empowering consumers to make important decisions about their health

Consumer-Initiated Testing (Table 5)

Consumer-initiated testing • Consumers can choose from approximately 60 different test purchase options focused on consumer interests, such as general health, men's and women's health, digestive health, heart health, infectious disease, sexually transmitted infection, COVID-19, and Lyme disease.

Expanded offerings • In 2022, we expanded our offerings to include, among others, new respiratory, thyroid, kidney and fitness tests.

Basic healthcare services • Comprehensive consumer health profile available, through tests and biometric measurements that provide a personalized health quotient score that can be used to track health progress over time.

Self-collection technology • Proprietary, consumer-friendly self-collection technology offered to consumers at home.

Convenient online access • In addition to access through QuestHealth.com, access to services through Walmart.com.

Convenient physical access • Access to services in our patient service centers and in select Walmart stores.

Drive operational excellence

We strive to enhance operational excellence and improve our quality and efficiency across every portion of our value chain and operations, from the time that we interact with a potential customer until the time we receive payment.

Major Themes to Drive Operational Excellence (Table 6)

Reduce denials and patient concessions Standardize, automate and optimize

Digitize the customer experience Select and retain talent

Improving our operations will yield many benefits, including:

enhancing customer experience;

improving our quality and competitiveness;

strengthening our foundation for growth;

and increasing employee engagement and shareholder value.

We are building a superior experience, at lower cost, for all of our customers, including consumers, health plans, IDNs and clinicians.

We endeavor to improve our processes and effectiveness at the same time.

We are guided by a service dashboard that focuses throughout our operations on quality for consumers, healthcare providers and employees, including medical quality, on-time delivery, competitive costs and employee safety.

During 2022, we made strong progress on our improvement initiatives.

We are working to further enhance end-to-end specimen tracking.

We concluded consolidation of our urinalysis testing onto a new highly automated platform.

We implemented new semi-automated technology in parasitology and are expanding use of a highly automated microbiology platform that makes use of artificial intelligence to assist with sample analysis.

We also made significant progress transferring immunoassay tests to a more automated platform, and expect to finish this project in 2023.

We increased customer adoption of our digital self-service channels, reducing demand in our call centers.

We implemented several initiatives to improve talent retention, including capability-building programs, and launched plans for a new daily management system for our frontline employees.

In addition, we continue to drive to take advantage of robotic process automation and artificial intelligence technologies to drive productivity gains.

Our cost excellence program, Invigorate, includes structured plans to drive savings and improve productivity across the value chain, including in such areas as revenue services, information technology and procurement.

We currently aim annually to achieve savings and productivity improvements of 3% of our costs.

In 2022, we approached our goal.

Unless the context otherwise requires, the terms “Quest Diagnostics,” “Quest,” the “Company,” “we” and “our” mean Quest Diagnostics Incorporated and its consolidated subsidiaries.

Our strategy aims to achieve two key goals:

generate growth and optimize our operating efficiency.

Our growth strategy focuses on continually developing solutions to meet the evolving needs of our customers.

We help people make the best decisions to improve health by providing high quality, innovative, convenient and affordable diagnostic testing insights and services using our scale and extensive reach.

We drive growth by:

• collaborating with healthcare providers and partners to leverage our broad access;

• offering an industry-leading menu of testing and other services;

• leveraging our data assets and services to improve population health and enable value-based care;

• continuously improving our quality and efficiency by leveraging the Quest Management System and by embracing innovative technologies, such as automation and artificial intelligence (AI).

Our growth strategy is focused on our primary customer channels – physicians, hospitals, patients and consumers – supported by Advanced Diagnostics™ (defined below), strategic acquisitions, and continuous quality improvement.

We serve approximately half the physicians in the United States each year.

We serve virtually all types of physicians from primary care physicians and internists to specialists, including rheumatologists, cardiologists, neurologists, and obstetricians/gynecologists.

We also serve physicians associated with accountable care organizations (“ACOs”), and Federally Qualified Health Centers (“FQHCs”).

Physicians determine which laboratory to recommend or use based on a variety of factors, but we believe that we provide the most attractive service offering in the industry, including the most comprehensive test menu, innovative test offerings, a positive customer experience, a staff including medical and scientific experts, high quality, leading access and distribution, and data-powered integrated information-technology solutions.

We believe that the growing market challenges faced by hospitals, including continued consolidation, price transparency, cost and utilization pressure, evolving healthcare payment models, capital needs, changing technology and limited resources, provide us with an opportunity to partner with them more effectively as they consider their laboratory testing strategy and drive demand for our expertise and services.

We serve approximately half the hospitals in the United States each year in many ways, including:

• Serving as a hospital lab’s laboratory.

In 2023, we generated over $1 billion in revenue from “reference testing,” where we perform testing that hospitals do not perform in their own in-hospital labs.

• Helping hospitals operate their labs more efficiently.

In 2023, our Professional Laboratory Services offering generated approximately $780 million in revenues and management fees supporting hospitals in the operation of their own labs.

Our key Professional Laboratory Services offerings include lab management outsourcing, test menu optimization and spend consolidation, supply chain management and providing, advanced data solutions.

• Acquiring outreach lab operations from hospitals.

Quest looks for opportunities to acquire assets of outreach lab operations from hospitals whose in-house labs have expanded from supporting in-patients to supporting out-patients and ambulatory patients who see physicians affiliated with the hospital.

We also have joint venture arrangements with leading hospitals and health systems.

These joint venture arrangements, which provide diagnostic information services for affiliated hospitals as well as for unaffiliated clinicians and other local healthcare providers, serve as our principal facilities in their service areas.

Typically, we have either a majority ownership interest in, or day-to-day management responsibilities for, our joint venture relationships.

Patients and Consumers

We have taken steps to be recognized as the consumer-friendly provider of choice of diagnostic information services.

Patients increasingly expect their healthcare experiences to be consumer-centric, which includes being more transparent,

accessible and convenient.

Most patients have a choice when selecting a diagnostic testing provider, and our goal is to provide leading services in conveniently located patient service centers that can provide a comprehensive suite of testing services.

Many of our 2,000 patient service centers are located inside large retail stores or in convenient retail settings across the United States.

We continue to enhance our operations to improve the patient experience in these locations.

For example, our "Schedule at Check In" capability encourages patients to make appointments, which allows us to better manage demand and productivity and has reduced average wait times in the patient service centers.

We also now provide mobile phlebotomy services in many parts of the United States so patients who prefer an in-home blood draw may access services for a fee.

We are also making investments to improve the consumer digital experience, from locating a patient service center to receiving results on our MyQuest ® patient healthcare portal.

We are also building the patient payment process into the digital customer experience, which not only improves the patient experience, but also helps our patient concession rate and reduces demands on phlebotomists.

In response to the growing consumer desire to be more directly involved in and have more control over their health outcomes, we provide our QuestHealth.com platform to allow health-minded consumers to purchase testing directly from us without first having to make a doctor’s appointment.

Consumers who want to evaluate their health or monitor certain chronic conditions, such as diabetes or hepatitis, as well as those seeking privacy can use these self-directed options to identify and more frequently monitor health issues than their health plan or other payer may be willing to reimburse.

A third-party physician reviews test orders and is available to consult with the consumer via a teleconsult about their test results.

We also provide opportunities for companies with telehealth and retail business models to rebrand our testing and utilize our patient service centers to provide access.

Other Customer Channels

Our other customer channels include health plans, employers, emerging retail healthcare providers, government agencies, pharmaceutical companies and other commercial clinical laboratories, which are described in more detail under “ – Customer Channels”.

While we principally focus on the U.S.

market, we serve customers globally and have a growing business that provides advanced reference testing to laboratory providers in other countries.

For more information about our operations, see “ – Business Operations”.

Advanced Diagnostics

We support the needs of all our customers with a focus on Advanced Diagnostics™.

Clinical laboratory testing can be characterized as routine, non-routine or advanced.

Non-routine tests are tests that may require professional “hands-on” attention from highly-skilled technical personnel, generally require more sophisticated data analysis, technology, equipment or materials, may be performed less frequently than routine tests and may be reimbursed at higher levels than routine tests.

Some non-routine tests are advanced (“Advanced Diagnostics™”).

Advanced Diagnostics™ includes certain procedures in the areas of molecular diagnostics (including next-generation sequencing), oncology, neurology, companion diagnostics and non-invasive pre-natal and other germline genetic testing.

We are a leading provider of Advanced Diagnostics™.

Our investments in our Advanced Diagnostics™ offerings enhance our innovation capabilities and strengthen our service offering, making our Advanced Diagnostics™ offerings more attractive and accessible to physicians and hospitals.

We are also seeking to apply the capabilities gained by these efforts to support other areas where we can make a meaningful difference in healthcare, including offerings to pharmaceutical companies and consumers.

We provide an array of Advanced Diagnostics™ offerings across the spectrum, including in high growth areas such as Molecular Genomics and Oncology.

We have a portfolio of oncology tests that includes traditional oncology screening and anatomic pathology, such as cervical cancer and skin cancer screening and diagnosis.

We are also well positioned to take advantage of advances in next generation sequencing to grow our business in cancer and other disease state testing.

This includes inherited genetics, newborn screening, and rare disease diagnosis, and solid tumor sequencing, such as to aid treatment selection and monitoring.

We are also particularly focused on the rapidly growing areas of monitoring recurrence and therapy effectiveness.

In 2023, we acquired Haystack Oncology, Inc.

("Haystack Oncology") a cancer testing company that has developed a highly sensitive testing technology for detecting minimal-residual disease (“MRD”) by circulating tumor DNA due to residual or recurring cancer.

Circulating tumor DNA (ctDNA) refers to tiny molecules of cancer shed by a solid tumor, such as colorectal or breast cancer, into the blood stream.

We believe this acquisition positions us well to compete in the higher-growth clinical area of ctDNA solid-tumor MRD testing.

In 2023, we also launched our QUEST AD-DETECT ® test portfolio for assessing Alzheimer's disease risk using blood specimens, as opposed to testing by more costly or invasive methods, such as testing of cerebral spinal fluid by lumbar puncture.

Acquisitions and Capital Deployment

Our strategy includes generating growth through value-creating, strategically aligned acquisitions using disciplined investment criteria.

We screen potential acquisitions using guidelines that assess strategic fit and financial considerations, including value creation, return on invested capital and impact on our earnings.

We endeavor to grow revenues each year by 1-2% through acquisitions.

We will continue to invest in our business in a disciplined manner, including focusing on enhancing our solid foundation of strategic assets and capabilities.

In 2023, we acquired Haystack Oncology, as well as certain assets of the laboratory services business of NewYork-Presbyterian, one of the nation's largest and most comprehensive academic medical centers.

We also completed our acquisition of select assets of Northern Light Laboratory, the outreach laboratory services business of Northern Light Health, a large integrated healthcare system in Maine.

Our significant acquisitions in each of the last three years are further discussed in Note 6 to the audited consolidated financial statements (Part II, Item 8 of this Report).

Acquisitions are part of our disciplined capital deployment framework, which also includes investment in our business, dividends and share repurchases and is grounded in maintaining an investment grade credit rating.

We expect to return a majority of our free cash flow to stockholders through a combination of dividends and share repurchases.

Consistent with that expectation, in February 2024, we announced that we increased our quarterly common stock cash dividend by approximately 5.6%, from $0.71 per common share to $0.75 per common share.

This represents our 13 th increase in the dividend since the beginning of 2012.

For many years, we have maintained a common stock repurchase program.

Since the beginning of 2012, we have returned approximately $7.5 billion to stockholders through repurchases of our common stock.

OUR STRENGTHS

We offer high value diagnostic information services and diagnostic solutions that are attractive to our customers.

Our Strengths (Table 7)

Quality Strong Operating Principles

Assets and Capabilities to Deliver Value Health Information Technology Solutions and

Information Assets

Innovation Medical and Scientific Expertise

Collaboration Customer Focus

Our goal is to provide every patient with services and products of superior quality.

We strive to accomplish that through commitment, leadership, and establishing rigorous processes that we measure and continually seek to improve, and by using the Quest Management System, which provides best-in-class business performance tools to create and implement effective and sustainable quality processes.

Continuous Quality Improvement

Our goal is to provide every patient and customer with services and products of superior quality.

We strive to accomplish that through rigorous processes that we measure and seek to improve, and by using the Quest Management System, which provides best-in-class business performance tools to create and implement effective and sustainable quality processes.

Our Quality Program includes policies and procedures to document, measure and monitor the effectiveness of our laboratory operations in providing and improving quality and meeting applicable regulatory requirements.

1 unchanged sentence

To help achieve our goal of becoming recognized as the undisputed quality leader in the diagnostics information services industry, we have implemented our Quality System Framework, which serves as a reference guide for our employees and describes our Quality System Elements, which provide the structure for each laboratory to achieve and maintain quality processes.

We also have a robust Supplier Quality Program designed to ensure we have a high-quality supplier network and to raise the bar of quality expectations across that network.

Being chosen by UnitedHealthcare as a participant in the UnitedHealthcare Preferred Lab Network reflects the strength of our quality.

For additional information about our commitment to quality, see "General - Quality Assurance" on page 25.

Strong operating principles

We have a foundation of three strong operating principles:

• strengthen organizational capabilities;

• remain focused on diagnostic information services;

• deliver disciplined capital deployment.

Strengthen organizational capabilities.

We continuously strive to strengthen our organizational capabilities to support our two-point strategy, enable growth and productivity, better focus on our customers, speed decision-making and empower employees.

Highlights include:

• Align for Growth, Execution and Efficiency .

Our organization is designed to align around growth opportunities, coordinate business units for seamless execution and leverage our company-wide infrastructure to gain more capability, value and efficiency.

We relied on this organizational design to allow us to develop a coordinated and sustained strategy to respond to the unprecedented challenges we face responding to the COVID-19 pandemic.

We also have a robust Supplier Quality Program designed to help us ensure we have a high-quality supplier network and to raise the bar of quality expectations across that network.

Operating Efficiency

We strive to enhance operational excellence and improve our efficiency across our value chain and operations, from the time that we first interact with a potential customer until the time we receive payment for our services.

Improving our operations can yield many benefits, including improving our quality and competitiveness, strengthening our foundation for growth, and increasing employee engagement and shareholder value.

Our cost excellence program, Invigorate, includes structured plans to drive savings and improve productivity across the value chain, including in such areas as patient services, logistics and laboratory operations, revenue services, information technology ("IT") and procurement.

Our Invigorate program has consistently delivered 3% of annual cost savings and productivity improvements, year in and year out to partly offset pressures from the current inflationary environment, including labor and benefit cost increases, and reimbursement pressures.

We are leveraging automation and AI to improve productivity, and also improve quality across our entire value chain, not just in the laboratory.

Other areas of focus include reducing denials and patient concessions, enhancing the digital experience, and selecting and retaining talent.

Organized to Drive Growth and Value

We strive to strengthen our organizational capabilities to align around growth opportunities, coordinate business units for seamless execution and leverage our company-wide infrastructure to gain more capability, value and efficiency.

The value creation side of our business includes product and commercial marketing and is organized by clinical franchise and focuses on customer solutions for the marketplace, including new test development and diagnostic insights.

Our clinical franchises – Cardiometabolic, Endocrine, and Wellness (CMEW), Drug Monitoring and Toxicology, Infectious Diseases and Immunology, Molecular Genomics and Oncology, Neurology, and Women’s and Reproductive Health – enable us to perform like a boutique laboratory while maintaining our scale advantages, and work with our research and development and commercial organizations to identify and deliver new and improved solutions.

The value delivery side includes sales, laboratory operations, field operations, logistics and client services.

• Quest Management System .

This system provides a foundation for day-to-day management, and includes best-in-class business performance tools to help develop new capabilities to improve our Company.

The system enables us to run the Company with a common language, approach and philosophy, and supports our efforts to maintain a high-performance culture, with employees focused on behaviors to foster our agility, transparency, customer focus, collaboration and performance orientation.

Remain focused on diagnostic information services.

We maintain a sharp focus on providing diagnostic information services.

Deliver disciplined capital deployment.

Our disciplined capital deployment framework includes investment in our business, dividends and share repurchases.

The framework is grounded in maintaining an investment grade credit rating.

We expect to return a majority of our free cash flow to investors through a combination of dividends and share repurchases.

Consistent with that expectation, in February 2023 we announced that we increased our quarterly common stock cash dividend by approximately 7.6%, from $0.66 per common share to $0.71 per common share.

This represents our twelfth increase in the dividend since 2011.

For many years, we have maintained a common stock repurchase program.

Since the beginning of 2013, we have returned approximately $7.1 billion to stockholders through repurchases of our common stock.

Our share repurchases, dividends and capital expenditures in each of the last three years are presented in our consolidated financial statements (Part II, Item 8 of this Report).

The Company's strategy includes generating growth through value-creating, strategically-aligned acquisitions using disciplined investment criteria.

We screen potential acquisitions using guidelines that assess strategic fit and financial considerations, including value creation, return on invested capital and impact on our earnings.

In 2022, we consummated the acquisition of Pack Health, a patient engagement company that helps individuals adopt healthier behaviors to improve outcomes, and the outreach testing business of Summa Health, a large integrated healthcare system in Northeastern Ohio.

We also agreed to acquire select assets of the outreach testing business of Northern Light Health, a large integrated healthcare system in Maine.

Our significant acquisitions in each of the last three years are further discussed in Note 6 to the audited consolidated financial statements (Part II, Item 8 of this Report).

We will continue to invest in our business in a disciplined manner, including focusing on enhancing our solid foundation of strategic assets and capabilities, accelerating growth and driving operational excellence.

Our near-term investments in growth are likely to focus on the approaches to accelerate growth set forth in table 2 above.

Our near-term investments to drive operational excellence are likely to focus on improving the customer experience and gaining efficiency, systems standardization, and digital enablement of our processes.

Assets and capabilities to deliver value

We use our unmatched size, scale and capabilities to deliver a very attractive value proposition to our customers.

Assets and Capabilities (Table 8)

Connectivity ● Provide healthcare connectivity solutions to >475,000 clinician and IDN accounts and interface with nearly 850 electronic health records systems

Data ● The largest private database of de-identifiable laboratory test results:

Assets and Capabilities that Deliver Value

We collaborate with partners and customers across the healthcare ecosystem to help create a healthier world.

The table below outlines some of the assets and capabilities that make us an attractive partner.

Assets and Capabilities

Connectivity ● Provide healthcare connectivity solutions to >518,000 clinician and hospital accounts and interface with >920 electronic health records systems

Data ● One of the largest private databases of de-identifiable laboratory test results:

>70 billion patient data points

2 unchanged sentences

• approximately 4,500 courier vehicles

• >20 aircraft serving the U.S.

Medical and Scientific Staff

● One of the largest medical and scientific staffs in the industry to provide interpretive consultation

• 19 aircraft serving the United States

Medical and Scientific Staff ● One of the largest medical and scientific staffs in the industry to provide interpretive consultation

• Approximately 700 M.D.s and Ph.D.'s, many of whom are recognized leaders in their field

• Genetic counselors

Other Healthcare Professionals

● Approximately 23,000 phlebotomists, paramedics, nurses and other health and wellness professionals

Consumer Access

● Approximately 7,300 patient access points, including phlebotomists in physician offices and the most extensive patient service center network in the U.S.

with approximately 2,100 locations

Health Plan Participation

● Access to approximately 90% of U.S.

Other Healthcare Professionals ● Approximately 23,000 phlebotomists, paramedics, nurses and other health and wellness professionals

Consumer Access ● Approximately 7,400 patient access points, including phlebotomists in physician offices, the most extensive patient service center network in the United States with approximately 2,000 locations, and mobile phlebotomy services

Health Plan Participation ● Access to approximately 90% of U.S.

insured lives

Processing Volume

● Processed approximately 208 million test requisitions in 2022, including approximately 15 million COVID-19 molecular test requisitions

Range of Testing

● Industry-leading test menu across clinical sub-specialty areas and diagnostic technologies

● Own or control approximately 1,100 issued and over 450 pending patents worldwide in 2022

We are a leading innovator in diagnostic information services.

We develop and introduce new tests, including many with a focus on personalized and targeted medicine, and new services.

Processing Volume ● Processed approximately 206 million test requisitions in 2023

Range of Testing ● Industry-leading test menu across clinical and pathology sub-specialty areas and diagnostic technologies

Patents ● Own or control approximately 1,200 issued and over 400 pending patents worldwide in 2023

Strong Relationships with Health Plans and Other Payers

Most of the services we perform are paid for by commercial payers, including large national health plans, regional and local health plans and government payers, which includes Medicare and Medicaid.

Through these payers, we estimate that we have access to approximately 90% of insured lives in the United States.

We work with payers to reduce the cost of care, improve the customer experience and drive better outcomes for patients.

We can strengthen our relationships with health plans and increase the volume of our services for their members by focusing on driving value and providing strong value propositions for members and physicians.

For example, we build information platforms to help health plans manage utilization and population health, keep laboratory testing in network and provide an alternative to high-cost labs.

We also offer extended care services to help close gaps in care designed to be attractive to payers.

We are a leading provider of innovation in diagnostic information services that help healthcare market participants care for their patients through better testing for predisposition, screening, monitoring, diagnosis, prognosis and treatment choices, and that can deliver high clinical value to the medical community and reduce the overall cost of healthcare.

We develop and introduce new tests through our research and development operations.

Our capabilities include discovery, technology development and clinical validation of diagnostic tests.

We also partner with other developers of new technologies, services and tests to transfer their innovations to the marketplace, using our in-house expertise ( e.g.

, strength in assay development and commercialization of testing services).

These developers include large commercial manufacturers, the academic community, pharmaceutical and biotechnology firms, emerging medical technology companies and others that develop and commercialize novel diagnostics, pharmaceutical and device technologies.

We maintain relationships with advisers and consultants who are leaders in key fields of science and medicine.

As the industry leader with the largest and broadest U.S.

network, we believe we are the distribution channel of choice for developers of new solutions.

Our clinical franchises enable us to perform like a boutique while maintaining our scale advantages, and work with our research and development and commercial organizations to identify/deliver new and improved solutions.

Clinical Franchises (Table 9)

Cardiovascular, Metabolic and Endocrinology Cancer Diagnostics

Infectious Diseases and Immunology Drug Monitoring and Toxicology

Neurology Women’s and Reproductive Health

We seek innovations and solutions that help healthcare providers, IDNs, health plans and other healthcare market participants care for their patients through better testing for predisposition, screening, monitoring, diagnosis, prognosis and treatment choices, and that deliver high clinical value to the medical community and reduce the overall cost of healthcare.

Starting with a clinical focus on a specific disease state or clinical problem, we take advantage of advanced technology for more precise, comprehensive and actionable information.

We seek to develop innovations and solutions that help to determine a patient's genotype or gene expression profile relative to a particular disease and its potential therapies, because they can help healthcare providers to determine a patient's susceptibility to disease or to tailor medical care to an individual's needs.

This would include determining if a medication might be an optimum choice for a particular person, or tailoring the right dosage once the proper medicine is prescribed.

, strength in new service development and commercialization of testing services).

These developers include large commercial manufacturers, the academic community, pharmaceutical and biotechnology firms, emerging medical technology companies, other laboratory companies and others that develop and commercialize novel diagnostics, pharmaceutical and device technologies.

Given our expertise and broad U.S.

network, we believe we are the distribution channel of choice for developers of new diagnostic information solutions.

Our innovation strategy focuses on new services and solutions for unmet clinical needs that will improve patient care and outcomes as well as economic value for patients, health plans and other payers.

We believe our research and development team includes several leaders in a number of fields, including in genomics, genetics and bioinformatics, as well as in disease states, such as oncology, neurology, cardiometabolic disease and other disorders.

We also maintain relationships with advisers and consultants who are leaders in key fields of science and medicine who advise us with our internal team of experts, complementing our expertise.

We endeavor to improve test processes, including through increased automation.

In addition, we aim to develop holistic solutions responsive to challenges that healthcare providers and patients face, by developing solutions of tests, information and services focused on specific clinical challenges, and taking advantage of the latest healthcare data capabilities.

We also look for innovations and solutions that are less invasive than currently available options, and to increase the choices that healthcare providers and patients have for the collection of diagnostic specimens.

We look to offer solutions from our large dataset and data analytics capabilities to help providers and health plans identify opportunities to optimize appropriate laboratory utilization, align clinical practice to medical guidelines, and inform patient-care decisions.

We also look for innovations and solutions that are more convenient, less invasive and more cost effective than currently available options.

We seek innovation in the ways we bring solutions to customers, and in the customer experience, including enhanced services and end-to-end solutions for convenience and support.

We make innovative solutions available to community physicians through our connectivity solutions, operational footprint and by making complex results actionable.

We plan to expand our innovative solutions through research and development, as well as partnerships with academic institutions, other technology and healthcare leaders and public health agencies.

During the COVID-19 pandemic, we secured numerous Emergency Use Authorizations from the FDA related to molecular diagnostic COVID-19 testing and, with government and private sector partners, developed and built "pop-up" COVID-19 testing sites that offered a new, efficient model for consumer access to testing.

In 2022, we innovated with the CDC Increasing Community Access to Testing for COVID-19 program to increase access to $0 out-of-pocket COVID-19 testing in underserved communities using a combination of our capabilities including our strong COVID-19 molecular testing, our on-line capabilities and our patient service centers.

We secured the first Emergency Use Authorization from the FDA during the Mpox (formerly known as Monkeypox) public emergency for an LDT to aid in the detection of Mpox.

We also launched a new obstetrics test panel that included hepatitis C screening.

These initiatives, along with other developments highlighted below under the headings "Collaboration," "Medical and Scientific Expertise," and "Healthcare Information Technology Solutions and Information Assets," demonstrate our agility and strength in innovation.

Collaboration

We believe that strategic relationships, including with healthcare providers, public health authorities, consumer-focused entities and others, can position us for growth at the center of healthcare and that healthcare companies that can partner effectively with others will be successful in the long term.

We collaborate with partners that can help us to achieve our vision of empowering better health through diagnostic insights and have relationships across the spectrum of healthcare, including with world class healthcare and consumer-focused leaders, to foster important advances in healthcare, including in precision medicine and healthcare delivery.

We plan to continue to pursue strategic relationships to help accelerate growth and drive operational excellence.

In 2022, we collaborated with IRIS (Intelligent Retinal Imaging Systems) to offer diabetic retinopathy screening services in our patient service centers, with Walmart to make consumer-initiated testing available through Walmart.com, and with eMed TM to launch a COVID-19 rapid antigen test with observed collection, to help individuals meet travel and other observed collection and test report requirements.

Medical and Scientific Expertise

2 unchanged sentences

They also publish research that demonstrates the clinical value and importance of diagnostic testing, including in connection with our research and development efforts, in peer-reviewed journals, textbooks and other publications.

For over 30 years, the Company has published the Quest Diagnostics Drug Testing Index, TM a series of reports on national workplace drug positivity trends based on the Company's employer workplace drug testing data, that is widely cited by employers, the federal government and the media to help identify and quantify drug abuse among the nation's workforce.

For over 30 years, the Company has published the Quest

Diagnostics ® Drug Testing Index, TM a series of reports on national workplace drug positivity trends based on the Company's employer workplace drug testing data, that is widely cited by employers, the federal government and the media to help identify and quantify drug abuse among the nation's workforce.

The Company also publishes Quest Diagnostics ® Health Trends, ® a series of scientific reports that provide insights into health topics, based on analysis of objective clinical laboratory data, to empower better patient care, population health management and public health policy.

Our role at the forefront of the response to the COVID-19 pandemic demonstrated this strength, as we secured numerous Emergency Use Authorizations from the FDA for innovations in connection with COVID-19 testing and specimen collection ( e.g.

, unobserved nasal specimen self-collection;

combined COVID-19 and influenza virus tests;

COVID-19 at-home specimen collection by consumers).

In 2022, we published more Health Trends ® reports on consequences of COVID-19, along with other reports on, for example, screening pregnant women for hepatitis C, and hepatitis B and tuberculosis co-infection.

We also published studies regarding diabetes cost reductions achieved for participants in employer-sponsored health programs, perspectives on the future of Alzheimer's Disease treatment and the potential importance of employee health to addressing the "Great Resignation." In addition, we employed our comprehensive menu of COVID-19 test and data analytics to support CDC population health research, helping to identify SAR-COV-2 seroprevalence on a multistate basis.

In 2023, we published Health Trends ® reports on lipid- associated risk of cardiovascular disease and, with the Centers for Disease Controls and Prevention (“CDC”), on hepatitis C infections in the United States.

Our annual Health Trends report on clinical drug testing revealed potentially dangerous mixing of the opioid fentanyl and the horse tranquilizer xylazine in clinically drug tested patients.

We are a founding member, with other leading diagnostic laboratories outside the United States, of the Global Diagnostics Network TM , a strategic working group of diagnostic laboratories committed to unleashing and sharing local innovation to increase global access to diagnostic science, information and services and generating enhanced diagnostic insights to improve the delivery of global healthcare.

With researchers from Johns Hopkins University and the other laboratories participating in the Global Diagnostics Network, we produced the largest analysis of cholesterol lipid levels, based on nearly half a billion de-identified, aggregated test results, to illuminate trends in cardiovascular disease in the United States and sixteen other countries.

Health Information Technology Solutions and Information Assets

We have a history of providing leading information technology for diagnostic information services, including for patients, clinicians and healthcare organizations.

We have a history of providing leading IT for diagnostic information services, including for patients, physicians and healthcare organizations.

We were the first national diagnostic information services provider to offer online patient appointment scheduling and a patient connectivity solution.

Our MyQuest ® patient healthcare portal, with more than 27.5 million registered users at year-end 2022, enables patients to manage healthcare and medical information for themselves and a circle of others and, among other things, use their smartphone or computer to order a test, find a Quest Diagnostics location, schedule appointments, receive appointment reminders, assess whether their health plan is in-network and receive and archive their test results.

Our MyQuest ® patient healthcare portal, with more than 32.9 million registered users at year-end 2023, enables patients to manage healthcare and medical information for themselves and a circle of others, find a Quest Diagnostics location, schedule appointments, receive appointment reminders, assess whether their health plan is in-network and receive and archive their test results.

Individuals can also use their smartphone or computer to order a consumer-initiated test from us at QuestHealth.com.

Our connectivity platform enables providers to order tests and receive results from us easily from up to 920 electronic health records.

We are expanding our use of digital and other technology tools to improve our customer experience for patients and providers.

We also were a founding member of the Synaptic Healthcare Alliance, which is working to create a platform, powered by blockchain technology, that enables a culture of innovation, removes friction and solves shared challenges impacting constituents across healthcare today.

We also have significant information assets and offer a robust portfolio of powerful analytics that inspire action and deliver value to an array of customers.

We offer an array of Quanum ® solutions based on data insights, including retrospective analytics solutions for healthcare professionals and practices, health plans, IDNs, pharmaceutical companies and public health organizations.

We believe that solutions can tap the potential of large amounts of clinical information to:

We offer an array of solutions based on data insights, including retrospective analytics solutions for physicians, hospitals, health plans, pharmaceutical companies and public health organizations.

We believe these solutions can tap the potential of large amounts of clinical information to:

enhance the customer experience;

4 unchanged sentences

We believe that the breadth and depth of our data, combined with our powerful analytics capabilities, enables us to take advantage of important data-based opportunities in diagnostics, and provides us a competitive advantage.

Customer Focus

Our brand idea -- Action from Insight ® -- reflects our commitment to a superior customer experience.

The customer is at the center of everything we do;

we strive to give them reason to put their trust in us.

We use customer insights in developing our approach, listening to the voice of customers to identify and implement solutions and processes that will result in a superior customer experience.

We also maintain our Everyday Excellence program, which includes guiding principles to support a superior customer experience, inspiring our employees to be their best every day, with every person and with every customer interaction.

Artificial Intelligence

We have a long history of using advanced technologies to automate processes, improve customer service, generate insights from lab and other data, and stimulate innovation.

We believe AI can help improve the quality of our screening and diagnostic capabilities.

For instance, we now use AI to help identify patterns in patient specimens evaluated for infectious microbes and chromosomal anomalies that may signify disease and are evaluating its potential to aid in evaluating specimens for signs of cancer.

We also believe that AI can help improve our operating efficiency.

In 2023, we created an initiative to deploy generative AI to improve several areas of our business, including software engineering, customer service, claims analysis, scheduling optimization, specimen processing and marketing.

We expect to further develop these projects in 2024.

We are committed to using AI in an ethical, responsible and compliant way.

We have implemented a formal AI Governance oversight committee and established multiple AI safeguards to minimize risks associated with AI, including, but not limited to, expanded security and privacy measures, increased user access controls, end user training and attestation, and standard operating procedures.

We seek to align our practices with the NIST AI Risk Management Framework (AI RMF) and strategically partner with external AI experts as needed to ensure we remain informed about the latest technological advancements in the industry.

Over time, we believe generative AI will help us innovate and grow in a responsible manner

while also enhancing customer and employee experiences and bring cost efficiencies.

We intend to continue to be at the forefront of the innovative, responsible and secure use of AI, including generative AI, in diagnostic information solutions.

A Commitment to Helping the Underserved

As part of our commitment to create a healthier world, we, along with our Quest Diagnostics Foundation, launched our Quest for Health Equity ® initiative, which aims to reduce health disparities in underserved communities in the United States through a combination of testing services, education programs, alliances and financial support.

Since its inception, we have committed approximately $38 million to more than 70 programs launched across the United States and Puerto Rico, including supporting community workforce development, COVID-19 testing and vaccination events, wellness events, educating young students on healthy nutrition choices and expanding research and mentorship opportunities for Black and Hispanic scholars.

Numerous Quest for Health Equity ® undertakings demonstrate our commitment to FQHCs and the people they serve, including by providing free lab testing services.

We are also looking at ways we can assist in addressing social determinants of health that can create barriers to healthcare for marginalized communities and other inequities in the healthcare system.

BUSINESS OPERATIONS

1 unchanged sentence

Diagnostic Information Services and Diagnostic Solutions.

Our Diagnostic Information Services business develops and delivers diagnostic information services, providing insights that empower and enable a broad range of customers, including those discussed in table 13.

Our Diagnostic Solutions group includes our risk assessment services business, which offers solutions for insurers, and our healthcare information technology businesses, which offers solutions for healthcare providers.

Our Diagnostic Information Services business develops and delivers diagnostic information services, providing insights from the results of our laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes.

Our Diagnostic Solutions group includes our risk assessment services business, which offers solutions for insurers, and our healthcare IT businesses, which offers solutions for healthcare providers and payers.

Our services primarily are provided under the Quest Diagnostics brand, but we also provide services under other brands, including AmeriPath, ® Dermpath Diagnostics, ® ExamOne, ® and Quanum.

We are the leading provider in the United States, where we conduct substantially all of our business, of clinical laboratory and anatomic pathology testing, and related services.

We are a leading provider of diagnostic information services in the United States, where we conduct substantially all of our business.

We see opportunities to bring our experience and expertise in diagnostic information services to markets outside the United States, including leveraging existing facilities to serve new markets.

We have laboratory facilities in Finland, Mexico and Puerto Rico.

We are a founding member, with other leading diagnostic laboratories outside the United States, of the Global Diagnostics Network, TM a strategic working group of diagnostic laboratories committed to unleashing and sharing local innovation to increase global access to diagnostic science, information and services and generating enhanced diagnostic insights to improve the delivery of global healthcare.

The Company and fellow members of the Network are focused on response to the COVID-19 pandemic and preparedness for future global infectious diseases.

Diagnostic Information Services

1 unchanged sentence

Clinical testing is an essential element in the delivery of healthcare services.

Clinical testing is used for predisposition, screening, monitoring, diagnosis, prognosis and treatment choices of diseases and other medical conditions.

Clinical testing is used for predisposition, screening, diagnosis, prognosis, monitoring, and treatment choices of diseases and other medical conditions.

Clinical testing is generally categorized as clinical laboratory testing and anatomic pathology services.

Anatomic pathology involves the diagnosis of cancer and other diseases and medical conditions through examination of tissue and cell samples taken from patients.

Clinical laboratory testing, which can be characterized as routine, non-routine or advanced, generally is performed on whole blood, serum, plasma and other body fluids, such as urine, and specimens such as microbiology samples.

2 unchanged sentences

Commonly ordered routine tests include blood chemistries, urinalysis, allergy tests and complete blood cell counts.

Non-routine tests may

require professional “hands-on” attention from highly-skilled technical personnel, generally require more sophisticated data analysis, technology, equipment or materials, may be performed less frequently than routine tests and may be reimbursed at higher levels than routine tests.

It may not be practical, from a cost-effectiveness or infrastructure perspective, for many IDNs, ACOs, commercial laboratories or physician office laboratories to develop and perform a broad menu of non-routine tests, or to perform low-volume non-routine testing in-house.

Non-routine tests may require professional “hands-on” attention from highly-skilled technical personnel, generally require more sophisticated data

analysis, technology, equipment or materials, may be performed less frequently than routine tests and may be reimbursed at higher levels than routine tests.

It may not be practical, from a cost-effectiveness or infrastructure perspective, for many hospitals, ACOs, commercial laboratories or physician office laboratories to develop and perform a broad menu of non-routine tests, or to perform low-volume non-routine testing in-house.

Such tests generally are outsourced to a clinical testing laboratory which can perform these non-routine tests.

Some non-routine tests are advanced.

Advanced tests include procedures in the areas of molecular diagnostics (including next-generation sequencing), oncology, neurology, companion diagnostics and non-invasive pre-natal and other germline genetic testing.

Some non-routine tests are Advanced Diagnostics.

Anatomic pathology involves the diagnosis of cancer and other diseases and medical conditions through examination of tissue and cell samples taken from patients.

Our services.

We are the world's leading provider of diagnostic information services.

We provide information and insights based on an industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services.

2 unchanged sentences

We believe that offering services, solutions and insights based on a full range of tests, information assets and other capabilities strengthens our market offering, market position and reputation.

We offer the broadest access in the United States to clinical testing.

We maintain a nationwide network of laboratories, including advanced laboratories as well as rapid response laboratories (smaller facilities where we can quickly perform an abbreviated menu of routine tests for customers that require rapid turnaround times).

We offer broad access to clinical testing through a nationwide network of laboratories, including advanced laboratories as well as rapid response laboratories (smaller facilities where we can quickly perform an abbreviated menu of routine tests for customers that require rapid turnaround times).

We operate 24 hours a day, 365 days a year.

Our nationwide network also includes patient service centers, phlebotomists in physician offices, and our connectivity resources, including call centers and mobile paramedics, nurses and other health and wellness professionals.

Our nationwide network also includes patient service centers, phlebotomists in physician offices, and our connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals.

Our large in-house staff of medical and scientific experts, including medical directors, scientific directors, genetic counselors and board-certified geneticists, provide medical and scientific consultation to healthcare providers and patients regarding our tests and test results, and help them best utilize our services to improve outcomes and enhance satisfaction.

We also provide testing (including anatomic pathology) services and medical director services at IDN laboratories.

We are a leading provider of diagnostic information services for infectious disease, such as COVID-19 (including molecular diagnostic and serology antibody offerings), tuberculosis ( e.g.

We also provide testing (including anatomic pathology) services and medical director services at hospital laboratories.

We are a leading provider of diagnostic information services for infectious disease, such as tuberculosis ( e.g.

, our T.SPOT.

1 unchanged sentence

, our Accutix™ offering).

We strive to be the first to provide diagnostic solutions for emerging infectious diseases ( e.g ., our offerings for Zika, West Nile Virus, SARS and Influenza A H1N1).

We have leading positions in drug monitoring and toxicology, in neurology diagnostics, in advanced cardiovascular diagnostic information services ( e.g ., our CardioIQ ® and Cleveland HeartLab ® offerings through our Cardiometabolic Center of Excellence TM ), and in cancer diagnostics ( e.g ., our QuestVantage ® offerings).

We are the largest workplace drug testing provider, testing urine, hair, and oral fluid specimens, and are certified by HHS to perform drug testing using electronic custody and control forms for federally-mandated, safety-sensitive workers.

We are a leading provider of employer population health services, including biometric screenings, flu shots and related preventative services that leverage clinical data to improve population health outcomes and reduce healthcare spend.

Our solutions enable employers to leverage screening insights to identify chronic disease risks, connect employees to needed in-network care, and empower better health.

Our offerings include connecting participants to the right care at the right time, such as (i) a program designed to prevent diabetes and other chronic conditions, (ii) a program that enables participants to engage with a board-certified physician about their results and to be guided about actions based on those results, (iii) a mental health assessment program that links participants to virtual support and (iv) a program to facilitate virtual telehealth access to clinical services for participants and adult dependents, with emphasis on reducing risks related to preventable chronic diseases.

These services are sold directly to employers and by health plan resellers.

In response to the COVID-19 pandemic, we developed and offered COVID-19 return to work services, to assist organizations developing plans for safer workplaces.

We offer Quanum ® health information technology solutions, including our products and national healthcare provider network, to help healthcare organizations and clinicians empower better health by leveraging the power of our significant information assets, including many years of test result data, and our technology prowess, including our history of providing leading information technology for diagnostic information services.

We strive to be the first to provide diagnostic solutions for emerging infectious diseases ( e.g ., our offerings for mpox virus).

We have comprehensive offerings in drug monitoring and toxicology, in neurology diagnostics, in advanced cardiovascular diagnostic information services ( e.g ., our CARDIO IQ ® and Cleveland HeartLab™ offerings through our Cardiometabolic Center of Excellence TM ), and in cancer diagnostics .

We also provide workplace drug testing services, testing urine, hair, and oral fluid specimens, and are certified by the U.S.

Department of Health and Human Services (“HHS”) to perform drug testing using electronic custody and control forms for federally-mandated, safety-sensitive workers.

We offer a wide range of employer population health services, including biometric screenings, flu shots and related preventative services that leverage clinical data to improve population health outcomes and reduce healthcare spend.

Our solutions enable employers to leverage screening insights to identify chronic disease risks, guide employees to needed in-network care, and improve employee health with intervention services.

Our offerings include connecting participants to the right care at the right time, such as (i) a program designed to prevent diabetes and other chronic conditions, (ii) a program that enables participants to engage with a board-certified physician about their results and be guided to the right next action based on those results, (iii) a health coaching program to help individuals adopt healthier behaviors to improve health outcomes and (iv) a program to facilitate virtual telehealth access to clinical services for participants and adult dependents, with emphasis on reducing risks related to preventable chronic diseases.

These services are sold directly to employers, through resellers and health plan partners.

We offer health IT solutions, including our products and national healthcare provider network, to help healthcare organizations and clinicians empower better health by leveraging the power of our significant information assets, including many years of test result data, and our technology prowess, including our history of providing leading IT for diagnostic information services.

Our portfolio of offerings is designed to address analytic, clinical and financial needs.

The solutions help healthcare organizations and clinicians analyze and put in context data, and enable them to connect across the healthcare system and engage with their stakeholders.

They can enter, share and access clinical information without costly information technology implementation or significant workflow disruption.

We offer population health solutions to clinicians, health plans, and IDNs.

They can enter, share and access clinical information without costly IT implementation or significant workflow disruption.

We offer population health solutions to clinicians, health plans, and hospitals.

Our services build on the power of our information assets and data capabilities and help our customers deliver better care to their patient populations by identifying gaps in care in a population, providing clinical solutions to close the gaps and fostering consumer engagement with a solution.

For example, Quest ® Lab Stewardship TM employs machine learning to help clinicians optimize medically-appropriate laboratory test utilization.

Our extended care services ( e.g ., bone density examinations;

home collection kits for lab testing) help deliver better care to patient populations by identifying and filling gaps in care for patient populations and by enabling delivery of the most effective healthcare to the right populations and individuals.

Our extended care services ( e.g ., home collection kits for lab testing) help deliver better care to patient populations by identifying and filling gaps in care for patient populations and by enabling delivery of the most effective healthcare to the right populations and individuals.

These services leverage the power of our assets ( e.g.

1 unchanged sentence

Once gaps are identified, we engage patients in our retail sites, in home or by telephone, including through our call centers and our mobile capabilities, including highly trained healthcare professionals.

In 2022, we enhanced our extended care offering by acquiring Pack Health, which offers patient engagement services that help individuals adopt healthier behaviors to improve outcomes.

We also enhanced our diabetic retinopathy screening offering, collaborating with IRIS (Intelligent Retinal Imaging Systems) to offer retinal imaging services in our patient service centers.

We offer services to pharmaceutical companies.

We offer clinical trials testing and have expertise in developing laboratory tests for FDA submission as companion diagnostics and laboratory developed tests for complementary diagnostics, and offer an array of assets and services to support the development of companion diagnostics, including our robust data set and patient services network.

We also offer Quest Clinical Trials Connect TM to help accelerate clinical trials (and thus the speed of drugs to market) through better patient recruitment, involvement and management, and improved physician outreach.

In 2022, we also began to offer Pack Health's patient engagement services to our pharma clients.

We also offer sports teams, including at the professional and collegiate levels, performance tools, based on biomarker testing, designed to optimize high-level athletic performance through actionable insights.

This service provides the context for athletes to consider performance variables holistically, including nutritional education and intervention, maximum fitness, injury assessment and training load monitoring as well as sophisticated biometric analysis.

During the COVID-19 pandemic, we also expanded our test offerings for athletes to include COVID-19 testing, to foster the country's return to athletic fields.

In 2022, we enhanced our extended care offering by acquiring Pack Health, LLC ("Pack Health") which offers patient engagement services that help individuals adopt healthier behaviors to improve outcomes.

We offer services to pharmaceutical companies, including clinical trials testing, and have expertise in developing laboratory tests for U.S.

Food and Drug Administration (“FDA”) submission as companion diagnostics and laboratory developed tests (“LDTs”) for complementary diagnostics, and offer an array of assets and services to support the development of companion diagnostics, including our robust data set and patient services network.

We also offer Quest Clinical Trials Connect™ to help accelerate clinical trials (and thus the speed of drugs to market) through better patient recruitment, involvement and management, and improved physician outreach.

We also offer Pack Health's patient engagement services to our pharma clients.

Diagnostic Solutions

Risk Assessment Services.

ExamOne ® is the largest provider of risk assessment services to the life insurance industry in North America.

Our risk assessment services comprise underwriting support services, including data gathering, paramedical examinations and clinical laboratory testing and analytics, designed to assist life insurance companies objectively to evaluate the mortality risks of applicants.

Most specimen collections and paramedical examinations are performed by our network of paramedical examiners at the applicant's home or workplace, but they also are offered at hundreds of Company patient service centers and many additional locations.

Healthcare Information Technology.

We offer healthcare organizations and clinicians robust health information technology solutions.

Our healthcare information technology offerings, including Quanum ® Practice Solutions, our Electronic Health Record, Practice Management and Revenue Cycle Management Solutions for healthcare providers, and our award-winning Quanum ® Enterprise Content Solutions for IDNs, connect data to decision-making and help clinicians advance clinical and operational strategies.

Our risk assessment service, ExamOne ® is the largest provider of risk assessment services to the life insurance industry in North America and comprises underwriting support services, including data gathering, paramedical examinations and clinical laboratory testing and analytics, designed to assist life insurance companies objectively to evaluate the mortality risks of applicants.

Most specimen collections and paramedical examinations are performed by our network of paramedical examiners at the applicant's home or workplace, but they also are offered at hundreds of our patient service centers and many additional locations.

ExamOne ® also offers other national specimen collection and health data solutions that provide fast and accurate insights for clinical research and diagnostics programs, as well as academic studies.

We also offer our award-winning Quanum ® Enterprise Content Solutions™ for hospitals, to connect data to decision-making and help clinicians advance clinical and operational strategies.

Healthcare organizations use Quanum ® Enterprise Content Solutions™ at approximately 745 sites in North America.

Our Quanum ® Electronic Health Record is a cloud-based, mobile-accessible offering that enables clinicians to generate a complete record of a clinical patient encounter, automates and streamlines the clinician's workflow, provides clinical decision support tools, captures patient encounter notes and lab and radiology results and enables secure communication with patients and other clinicians.

THE CLINICAL TESTING INDUSTRY

The healthcare system in the United States is evolving.

We expect that the evolution of the healthcare industry, including impacts of the COVID-19 pandemic, which include the increased adoption of telemedicine, will continue, and that industry change is likely to be extensive.

There are a number of key trends that we expect will continue to have a significant impact on the diagnostic information services business in the United States and on our business.

The healthcare system in the United States continues to evolve and industry change is likely to be extensive.

Because diagnostic information services is an essential healthcare service, we believe that the industry will continue to grow over the long term.

There are a number of key trends that we expect will continue to have a significant impact on the growth and the nature of the diagnostic information services business in the United States and on our business.

These trends, discussed in the table below, present both opportunities and risks.

We believe that several of the trends, including consolidation, price transparency and consumerization, are favorable to our business.

Because diagnostic information services is an essential healthcare service and because of the key trends discussed below, we believe that the industry will continue to grow over the long term.

In addition, we believe that the clinical testing market continued with fundamental changes in 2022.

First, we believe that PAMA-driven reimbursement pressure is a catalyst for structural change in the market.

Second, we believe that there is an increased focus among our customers, including health plans, ACOs and government programs, on driving value in connection with laboratory testing services.

Third, we believe that ongoing consumerization in healthcare, with increased cost being borne by consumers, is changing consumption of healthcare services.

We believe that these changing market fundamentals will benefit lower-cost, high-value providers like Quest and that we are well positioned to grow from the changing market conditions and benefit from the long-term growth expected in the industry.

Key Trends (Table 11)

PAMA-driven reimbursement pressure Pursuant to PAMA, reimbursement rates for many clinical laboratory tests provided under Medicare were reduced during 2018 - 2020.

PAMA calls for further revision of the Medicare Clinical Laboratory Fee Schedule for years after 2020, based on future surveys of market rates;

Reimbursement pressure driven by The Protecting Access to Medicare Act of 2014 (“PAMA”) Pursuant to PAMA, reimbursement rates for many clinical laboratory tests provided under Medicare were reduced during 2018 - 2020.

Unfortunately, as a result of a flawed implementation of PAMA, the data collected did not accurately represent the laboratory market as required under PAMA.

Independent laboratories were overrepresented, and hospitals and physician office laboratories were underrepresented, making the first round of PAMA cuts too extreme and resulting in below market rates.

PAMA calls for further revision of the Medicare Clinical Laboratory Fee Schedule (“CLFS”) for years after 2020, based on future surveys of market rates.

PAMA's next data collection and reporting period have been delayed, most recently by federal legislation adopted in November 2023 (the Further Continuing Appropriations and Other Extensions Act of 2024), which further delayed the reimbursement rate reductions and reporting requirements until January 1, 2025;

reimbursement rate reduction from 2025-27 is capped by PAMA at 15% annually.

PAMA's next data collection and reporting period have been delayed, most recently by federal legislation adopted in December 2022, which further delayed the reimbursement rate reductions and reporting requirements until January 1, 2024.

Health plans driving value in lab spending IDNs, which provide outreach testing and may encourage clinicians to send their outreach testing volume to the IDN's laboratory, historically were able to negotiate higher reimbursement rates with health plans than commercial clinical laboratories for comparable services.

In addition, health plans generally reimburse non-participating laboratory testing providers at higher out-of-network rates.

Congress reintroduced federal legislation in 2023 (the Saving Access to Laboratory Services Act), which, if enacted, would reform PAMA and create a true market-based CLFS.

Health plans driving value in lab spending Some hospitals provide outreach testing and may encourage clinicians to send their outreach testing volume to the hospital's laboratory.

Historically, hospitals were able to negotiate higher reimbursement rates with health plans than commercial clinical laboratories for comparable services.

In addition, health plans generally reimburse laboratory services provided by non-participating laboratories at higher out-of-network rates.

We are finding increased interest among health plans in driving better value in spending for laboratory testing.

Health plans increasingly are taking steps to encourage the movement of testing volume to high value, lower cost providers like our Company, including by identifying preferred provider partners, plan design changes ( e.g ., zero-dollar out-of-pocket costs for members using preferred providers) and better aligning reimbursement rates for IDN-based providers and independent commercial laboratories.

Health plans increasingly are taking steps to encourage the movement of testing volume to high value, lower cost providers like our Company, including by identifying preferred provider partners, plan design changes (e.g., zero-dollar out-of-pocket costs for members using preferred providers) and better aligning reimbursement rates for hospital-based providers and independent commercial laboratories.

The UnitedHealthcare Preferred Lab Network, which chose us to participate, is an example of a health plan taking these steps.

Health plans also are increasingly adopting policies, practices and procedures based on requirements imposed by government payers such as Medicare and Medicaid in order to influence the utilization and reimbursement of testing services.

These policies, practices and procedures are subject to change without notice.

Health plans also are increasingly adopting policies, practices and procedures and incorporating requirements imposed by government payers such as Medicare and Medicaid that influence the utilization and reimbursement of testing services.

These policies, practices procedures and requirements are often subject to change without notice.

Consumerization Consumers are our customers.

1 unchanged sentence

As a result, they are becoming more sophisticated in their understanding of their healthcare needs and their expectations of healthcare providers.

Some consumers are interested in selecting their own diagnostics tests, rather than relying upon a healthcare professional to select the tests.

In addition, consumers often are bearing increased financial responsibility for their healthcare (e.g., high deductible health plans;

2 unchanged sentences

Consumers increasingly are demanding convenience and a superior and personalized experience relevant to their needs.

During the COVID-19 pandemic, we saw consumers increase their use of telemedicine capabilities, increase their responsibility for their own healthcare ( e.g.

, increased consumer-initiated testing;

During the COVID-19 pandemic, we saw consumers increase their use of telemedicine capabilities, increase their responsibility for their own healthcare (e.g., increased consumer-initiated testing;

increased specimen self-collection) and increase their openness to new delivery channels (e.g., retail;

4 unchanged sentences

Prevention and wellness We believe that the value of detection, prevention, wellness and personalized care is well recognized.

Government agencies and other customers discussed in table 13 increasingly focus on helping the healthy stay healthy, detecting symptoms among those at risk and providing preventive insight and care that helps avoid or reduce the negative impacts of a disease.

Government agencies and other customers discussed herein increasingly focus on helping the healthy stay healthy, detecting symptoms among those at risk and providing preventative insight and care that helps avoid or reduce the negative impacts of a disease.

Medical innovation Medical developments are creating new opportunities and new challenges and disrupting the healthcare environment.

For example, during the COVID-19 pandemic, telemedicine practices became more commonly used and digital pathology is an emerging technology that may change the practice of pathology.

Information technology that includes self-learning or "artificial intelligence" features is growing and impacting healthcare.

For example, digital pathology is an emerging technology that may change the practice of pathology.

IT that includes self-learning or AI features is growing and impacting healthcare.

Continuing advances in genomics and proteomics are expected to give rise to new, more sophisticated and specialized diagnostic tests.

These advances also are spurring interest in and demand for precision medicine, which relies on diagnostic and prognostic testing and in which data information services and strategies are used to deliver the most effective healthcare to the right populations and individuals.

Pharmacogenomic testing increasingly is used as a parameter to help speed drug approval processes and to better focus therapy based on patient and tumor-specific genetic markers.

For example, we expect to help expand patient access to diagnostic services advancing precision medicine for rheumatoid arthritis based on a novel test developed by Scipher Medicine, a precision immunology company.

We also look for innovations and solutions that are more convenient, less invasive and more cost effective than currently available options.

For instance, our QUEST AD-DETECT ® test portfolio for assessing Alzheimer’s disease risk uses blood specimens, as opposed to testing by more costly or invasive methods, such as testing of cerebral spinal fluid by lumbar puncture.

In 2023, we acquired Haystack Oncology, a cancer testing company that has developed a highly sensitive testing technology for detecting MRD due to residual or recurring cancer.

A collaboration with Rutgers University involving our Haystack MRD™ technology is expected to help evaluate therapeutic response and provide molecular insights for a clinical trial of certain patients treated for breast cancer.

Through a collaboration with Sarepta Therapeutics, a leader in precision genetic medicine for rare diseases, we developed and were granted Breakthrough Device Designation from the FDA for a test to help identify patients eligible for treatment with a Sarepta-created gene therapy for certain individuals with Duchenne muscular dystrophy.

Demand also is growing toward comprehensive care management solutions that serve patients, payers and healthcare providers by improving clinical decision support and access to patient data, and by increasing patient participation in care management and population health management.

1 unchanged sentence

Healthcare industry evolution;

focus on value Customers discussed in table 13 and other healthcare system participants have been consolidating, converging and diversifying.

For example, a number of IDNs are considering establishing or have established health insurance plans, and health insurance providers are considering providing or are providing healthcare services.

In recent years, a leading provider of retail medical clinics and pharmacy benefits management services has acquired a leading health insurance provider, a leading health insurance provider has acquired a leading pharmacy benefits manager, leading providers of retail pharmacy services have acquired, or agreed to acquire, significant ownership stakes in physician practices, and the corporate parent of a leading health insurance company provides a wide array of healthcare services through its non-insurance company subsidiaries and is collaborating with the nation's largest retailer.

Health plans are entering agreements with other providers of healthcare services, including laboratory testing services providers, to partner on value-based approaches to delivering healthcare to populations.

Consolidation is increasing pricing transparency and bargaining power, and may encourage internalization of clinical testing.

Physicians frequently now are employed by IDNs, ACOs or large group practices integrated with IDNs, instead of organizing physician-owned practices, which is impacting the dynamics for whether clinical testing is performed in or outside of an IDN.

Physicians and other clinicians also increasingly are being employed by health plans, large retailers or their affiliates.

focus on value Consolidation in the healthcare industry has continued, including among our customers.

Certain of our customers are seeking to diversify their service offerings and to partner with other providers to offer value-based care alternatives.

Consolidation is increasing pricing transparency, and may encourage internalization of clinical testing.

Physicians frequently now are employed by hospitals, ACOs or large group practices integrated with hospitals, instead of organizing physician-owned practices, which is impacting the dynamics for whether clinical testing is performed in or outside of a hospital.

Physicians and other clinicians also increasingly are being employed by health plans, large retailers, other non-traditional industry entrants (e.g., private equity firms) or their affiliates.

Value-based reimbursement and demand for convenience and greater availability are contributing to changes in the healthcare system.

ACOs and patient-centered medical homes have grown as a means to deliver patient care.

CMS has refreshed its strategy to reinvigorate the national push toward value-based care for Medicare and Medicaid beneficiaries, and set goals for value-based reimbursement to be achieved.

Centers for Medicare and Medicaid Services (“CMS”) has refreshed its strategy to address the national push toward value-based care for Medicare and Medicaid beneficiaries, and set goals for value-based reimbursement to be achieved.

CMS has stated that the Medicare Sharing Savings Program for ACOs is a critical component of CMS' vision to advance health equity, drive high-quality, person-centered care and promote affordability and sustainability of the Medicare program.

CMS sponsors two additional programs for ACOs, has stated that its goal is for all people in traditional Medicare to be in an ACO by 2030, and is adopting policies to drive growth in ACO participation.

CMS has stated that its goal is for all people in traditional Medicare to be in an ACO by 2030, and is adopting policies to drive growth in ACO participation.

Changes also are taking place in the way that some healthcare services are purchased and delivered in the United States.

IDNs are under significant pressure, and IDNs and large retailers are evolving.

Healthcare services increasingly are being provided by non-traditional providers ( e.g.

, physician assistants), in non-traditional venues ( e.g ., retail medical clinics, urgent care centers) and using new technologies ( e.g.

, telemedicine, digital pathology).

Hospitals are under significant pressure, and hospitals and large retailers are evolving.

Healthcare services increasingly are being provided by non-traditional providers (e.g., physician assistants), in non-traditional venues (e.g., retail medical clinics, urgent care centers) and using new technologies (e.g., telemedicine, digital pathology).

Pricing transparency There has been a trend toward greater pricing transparency in healthcare, including in the laboratory testing marketplace.

1 unchanged sentence

For example, Massachusetts launched a website to help consumers understand the wide variation in healthcare costs.

Federal laws require health care providers to provide good faith estimates of costs to self-pay patients, and provide rights and protections for consumers against surprise billing or balance billing.

Federal laws require healthcare providers to provide good faith estimates of costs to self-pay patients, and provide rights and protections for consumers against surprise billing or balance billing.

In addition, the federal government has adopted new legislation and issued new regulations designed to increase transparency regarding pricing and quality in healthcare, including requiring providers, group health plans and insurers to disclose cost information to consumers in advance of care being provided.

1 unchanged sentence

We believe that increased price transparency should benefit lower cost, high value providers like our Company.

Competition The diagnostic information services industry remains fragmented, is highly competitive and is subject to new competition.

Competition The diagnostic information services industry remains fragmented, highly competitive and subject to new competitors.

Competition is emerging from new technologies (e.g., digital pathology) and growing from non-traditional competitors (e.g., a government agency or an employer establishing its own clinical laboratory for testing;

providers of consumer-initiated testing).

Increased IDN acquisitions of physician practices may enhance clinician ties to IDN-affiliated laboratories and may strengthen their competitive position.

However, in light of other trends, including continued reimbursement pressure, IDNs may change their approach to providing clinical testing services.

New industry entrants with extensive resources may make acquisitions or expand into our traditional areas of operations.

Increased hospital acquisitions of physician practices may enhance clinician ties to hospital-affiliated laboratories and may strengthen their competitive position.

However, in light of other trends, including continued reimbursement pressure, hospitals may change their approach to providing clinical testing services.

New industry entrants with extensive resources (e.g., private equity firms) may make acquisitions or expand into our traditional areas of operations.

Healthcare utilization

Healthcare utilization in the United States has fluctuated based on a number of factors.

These factors include, without limitation, the economy, healthcare benefits design, patients delaying medical care ( e.g ., due to the COVID-19 pandemic), and increased consumer financial responsibility for, interest in and control of their healthcare.

These factors include, without limitation, the economy, healthcare benefits design, patients delaying medical care, and increased consumer financial responsibility for, interest in and control of their healthcare.

Reimbursement pressure;

3 unchanged sentences

There is increased market activity regarding alternative payment models, including bundled payment models.

The Health Transformation Alliance, initially a group of over 50 major U.S.

companies, was formed to improve and reform the healthcare system in the United States.

The rising cost of healthcare in the United States was a key driver for the formation of this alliance.

While pressure to control healthcare costs poses a risk to our Company, it also creates opportunities, such as an opportunity for increased proper utilization of testing as an efficient means to manage the total cost of healthcare.

3 unchanged sentences

The FDA and HHS have expressed views regarding the regulation of LDTs.

Legislation introduced in recent sessions of Congress that would authorize the FDA to regulate LDTs has not become law.

If legislation that authorizes the FDA to regulate LDTs were to become law, it could have a significant impact on the clinical laboratory testing industry, including regulating LDTs in new ways, while creating avenues of opportunity and competition regarding clinical laboratory testing.

Legislation previously introduced in Congress in 2022 and again in 2023 that would authorize the FDA to regulate LDTs has not become law.

In October 2023, the FDA announced a proposed rule that would broaden the definition of medical device to include diagnostic tests and laboratories that develop them.

Publication of a final rule initiates a four-year period for a staged process of compliance and submissions.

The proposed rule could also impact a revitalization and passage of legislation that authorizes the FDA to regulate LDTs by amending the Food, Drug and Cosmetic Act.

If either the rule or legislation were to become law, it could have a significant impact on the clinical laboratory testing industry, including regulating LDTs in new ways, while creating new avenues of opportunity and competition regarding clinical laboratory testing.

New competitors may enter the industry, and competition may come in new forms.

From time to time, the federal government has considered whether competitive bidding could be used to provide clinical testing services for Medicare beneficiaries while maintaining quality and access to care.

Congress periodically considers cost-saving initiatives.

These initiatives have included coinsurance for clinical testing services, co-payments for clinical testing and further laboratory physician fee schedule reductions.

Use of healthcare data;

2 unchanged sentences

We provide automated next generation genetic sequencing, which will enable genetic screening faster and at lower cost.

Use of healthcare data, including integrated diagnostic and decision support solutions, predictive analytics, and healthcare information technology, is spurring advances in precision medicine, including medical decision making and value, for populations and individuals.

Use of healthcare data, including integrated diagnostic and decision support solutions, predictive analytics, and healthcare IT, is spurring advances in precision medicine, including medical decision making and value, for populations and individuals.

The increased focus on data and its use is increasing focus on maintaining the privacy of patient data.

There is a need for technology solutions to harness these opportunities.

In addition, new technology, social media and mobile technology are changing the way that healthcare markets interact with each other, and the expectations that they have about how services are provided, what services are provided, and other capabilities of healthcare market participants.

These developments are creating new opportunities and new challenges and disrupting the healthcare environment.

For example, during the COVID-19 pandemic, telemedicine practices became more commonly used and digital pathology is an emerging technology that may change the practice of pathology.

Information technology that includes self-learning or "artificial intelligence" features is growing and impacting the healthcare industry.

Healthcare market participants, including many of our customers discussed in table 13, are striving to leverage interoperability and healthcare data analysis to positively influence the health of patient populations while maintaining patient privacy.

We are subject to certain federal and state regulations that impose interoperability requirements.

Healthcare market participants, including many of our customers discussed herein, are striving to leverage interoperability and healthcare data analysis to positively influence the health of patient populations while maintaining patient privacy.

Use of technology, including AI New technology, social media and mobile technology are changing the way that healthcare markets interact with each other, and the expectations that they have about how services are provided, what services are provided, and other capabilities of healthcare market participants.

We have experience using advanced technologies, including AI, to automate processes, improve customer service, generate insights from lab and other data, and stimulate innovation.

We believe AI can help improve the quality of our screening and diagnostic capabilities, as well as our operating efficiency, and expect to continue to be at the forefront of the innovative, responsible and secure use of AI, including generative AI in the diagnostic information services market.

These technology developments are creating new opportunities and new challenges, disrupting the healthcare environment.

Chronic diseases and conditions;

1 unchanged sentence

As a result of multiple factors, including increased focus on population health management and pressure to reduce the systemic costs associated with such diseases and conditions, there is increased focus on better identifying and attempting to reduce or eliminate the gaps in care historically associated with these diseases and conditions.

Healthcare market participants are developing new approaches for this purpose.

As a result of the COVID-19 pandemic, there has been an increase in delays in diagnosis and treatment of chronic diseases and conditions, particularly in underserved communities, increasing potential gaps in care.

The COVID-19 pandemic called attention to gaps in care of these conditions in underserved populations;

we believe that there also is increased focus on reducing or eliminating these gaps in care.

Healthcare services delivery Healthcare delivery is moving out of hospitals, clinician offices and other traditional locations in which it had been provided.

Care is increasingly being provided in new settings, such as outpatient, retail, consumer-focused and home settings.

In response to the COVID-19 pandemic, telemedicine practices became more commonly used.

This dynamic offers new opportunities and challenges for healthcare providers and reflects not only efforts to take advantage of new technologies, but also the trends of consumerization and affordability, each of which are discussed above in this table.

The Value of Diagnostic Information Services

In view of the key trends discussed in table 11, healthcare providers, consumers and payers increasingly recognize the value of diagnostic information services as a means to help achieve the triple aim of healthcare:

improving medical quality and the patient experience while reducing the cost of care.

The CDC states that 70% of today's medical decisions depend on laboratory test results.

Table 12 highlights how diagnostic information services contribute to improving medical quality and the patient experience while reducing healthcare costs.

Helping to Achieve the Triple Aim of Healthcare (Table 12)

• Detect the symptoms of disease earlier (by identifying patients at risk for disease before they require urgent care, hospital treatment or expensive therapies)

• Aid in the choice of therapeutic regimen (by helping clinicians to target the right medicines for the right patients at the right time)

• Identifying treatment-related side effects

• Monitor patient compliance

• Evaluate treatment results ( e.g ., assessing early the efficacy of a therapy, enabling changes or discontinuation of ineffective therapies)

• Enabling population health management by identifying gaps in care and delivery of targeted solutions to individuals who need care

• Identifying and proactively managing individuals at risk for diseases, to decrease progression and associated costs and morbidity

• Help individuals obtain and interpret appropriate advice and referrals into needed care

We provide diagnostic information services to a broad range of customers, including those discussed in table 13.

As discussed in table 11 above, customers are consolidating, converging and diversifying.

In many cases, the customer that orders our services is not responsible for paying for these services.

Depending on the billing arrangement and applicable law, the payer may be the patient or a third party, such as a health plan, Medicare or a Medicaid program.

Healthcare market participants, including Quest, are developing new approaches for this purpose.

Healthcare services delivery Healthcare delivery is moving out of hospitals, clinician offices and other traditional locations into new settings, such as outpatient, retail, consumer-focused, telemedicine and home settings.

This dynamic offers new opportunities (e.g., mobile phlebotomy services) and challenges for healthcare providers.

We are seeking opportunities to provide diagnostic information services to these new healthcare service providers.

We believe that these changing market fundamentals will benefit lower-cost, high-value providers like Quest, and that we are well positioned to grow from the changing market conditions and benefit from the long-term growth expected in the industry.

Customer Channels

We provide diagnostic information services to a broad range of customers within our primary customer channels of physicians, hospitals, and patients and consumers.

In many cases, the individual that orders our services is not responsible for paying for these services.

Increasingly, patients are bearing greater responsibility for some portion of the payment for the services we provide to them, even if a third party is primarily responsible for payment.

In addition, consumers are more frequently taking advantage of offerings like the Company's QuestHealth TM offering, and requesting and paying for tests themselves.

Customers (Table 13)

Clinicians Clinicians ( e.g ., primary care physicians, specialists and physician assistants) requiring diagnostic information services for patients are the primary referral source for our services when patients choose their diagnostic information services provider.

In recent years, there has been a marked increase in the number of physician practices owned by IDNs.

In addition, consumers are more frequently requesting and paying for tests themselves.

In the table below, we provide a summary of our different customer channels.

For more information on our growth strategy supporting these customer channels, see above under the heading “Our Strategy".

Customer Channels

Physicians, including those associated with ACOs and FQHCs Physicians and physician assistants requiring diagnostic information services for patients are the primary referral source for our services.

For more information see "Our Strategy --Physicians".

In recent years, there has been a marked increase in the number of physician practices owned by hospitals.

There also has been a notable increase in some branches of medicine of the establishment of very large "rolled-up" physician practice groups.

IDNs that own physician practices may encourage or require the practices to refer outreach testing to the IDN's affiliated laboratory.

Hospitals that own physician practices may encourage or require the practices to refer outreach testing to the hospital's affiliated laboratory.

Large specialty physician groups may encourage their members to refer testing to other members of the group or to a lab owned by the large physician group.

In each case, referrals to independent diagnostic services providers may be reduced.

Clinicians determine which laboratory to recommend or use based on a variety of factors, including those set forth in table 14.

Health plans including managed care organizations and other health insurance providers These customers typically reimburse us as a contracted (or out-of-network) provider for services rendered to their members.

In certain locations, health plans may delegate to IPAs or other alternative delivery systems ( e.g ., physician IDN organizations, ACOs, patient-centered medical homes) the ability to negotiate for diagnostic information services on behalf of certain members.

Increasingly, these customers are interested in value-based arrangements.

Health plans and IPAs often require that diagnostic information services providers accept discounted fee structures or assume all or a portion of the financial risk associated with providing such services through capitated payment arrangements.

Under capitated payment arrangements, we provide services at a predetermined monthly reimbursement rate for each covered member, generally regardless of the number or cost of services provided by us.

Under some capitated programs, we may provide certain services on a negotiated fee-for-service basis.

Reimbursement under programs that do not provide for capitated payments is typically negotiated on a fee-for-service basis.

Reimbursement from our five largest health plans totaled approximately 20%, and no one health plan accounted for 10%, of our consolidated net revenues in 2022.

Health plans typically negotiate directly or indirectly with a number of diagnostic information services providers, and represent approximately one-half of our total clinical testing volume and approximately 45% of our net revenues from diagnostic information services.

There has been a trend of consolidation among health plans.

Some health plans also have narrowed their provider networks.

In addition, some health plans have established "preferred provider" networks within their broader networks (e.g., UnitedHealthcare's Preferred Lab Network), in effect distinguishing among contracted providers.

We are also sometimes a member of a “complementary network.” A complementary network generally is a set of contractual arrangements that a third party maintains with various providers that provide discounted fees for the benefit of its customers.

A member of a health plan may choose to access a non-contracted provider that is a member of a complementary network;

if so, the provider will be reimbursed at a rate negotiated by the complementary network.

We offer to health plans services and programs that leverage our Company's expertise and resources, including our superior patient access, extensive test menu, medical staff, data, information technology solutions, and wellness and population health management capabilities.

For the last few years, our Company has had access to a very high percentage of the insured lives in the U.S., including very strong access in key high-population states.

We believe that this strong access increases our attractiveness to other customer groups, including clinicians, patients and employers.

IDNs We believe that we are an industry leader in servicing hospitals.

We provide services to IDNs throughout the United States, including advanced testing services, in some cases managing or serving as the medical directors of their laboratories (including through our industry-leading Professional Lab Services offering discussed in table 3 above).

IDNs generally maintain an on-site laboratory to perform the significant majority of clinical testing for their patients (inpatients and outpatients) and refer certain testing to outside service providers, which typically charge the IDNs on a negotiated fee-for-service basis.

Fee schedules for IDN reference testing services often are negotiated on behalf of IDNs by group purchasing organizations.

We also have joint venture arrangements with leading IDNs.

These joint venture arrangements, which provide diagnostic information services for affiliated IDNs as well as for unaffiliated clinicians and other local healthcare providers, serve as our principal facilities in their service areas.

Typically, we have either a majority ownership interest in, or day-to-day management responsibilities for, our joint venture relationships.

In light of continued pressure to reduce systemic healthcare costs, IDNs may change their approach to providing clinical testing services, including by insourcing tests, seeking ways to improve profitability or to better utilize their laboratory capacity.

We believe that our combination of services positions us to be an attractive partner for IDNs, offering a full range of strategic relationships.

ACOs An ACO is a network of providers and facilities that share financial risk in providing or arranging for the provision of healthcare.

We also serve physicians associated with ACOs and FQHCs.

An ACO is a network of providers and facilities that share financial risk in providing or arranging for the provision of healthcare.

ACO members collaborate to provide coordinated, high-quality care to their patients;

6 unchanged sentences

In addition, we believe that our extended care experience and population health capabilities are attractive to ACOs, and that our Quest for Health Equity ® initiative underscores our commitment to health equity important to ACOs.

Employers Employers use tests for drugs of abuse to determine an individual's employability and “fitness for duty.” Companies with high levels of employee hiring, safety conscious environments or regulatory testing requirements provide the highest volumes of testing.

Factors such as the general economy, the job market and changes in the legal environment ( e.g ., marijuana legalization or decriminalization) can impact the utilization of drugs-of-abuse testing.

Some employers retain third party administrators to handle such testing and related services;

we support the needs of third party administrators as well as employers who retain us directly.

Employers also are investing in population health services.

We meet their needs by providing nationwide access to our customizable services (discussed above at page 13), directly and through health plan and health improvement providers.

These services help employers, employees and others manage healthcare costs, capitalize on trends in personalized health and improve health outcomes.

We seek to grow our employer business through offering new and innovative programs to help them with their goals of (1) maintaining a safe and productive workplace, (2) improving healthcare for employees and (3) lowering healthcare costs for employees and employers.

Consumers We are well positioned to provide information and insights to individual consumers to help empower them take actions to improve their healthcare.

The changing expectations of individual consumers about their healthcare and their healthcare transactions are influencing our services and the way we provide them.

See the discussions of our consumer strategy at page 5 and consumerization above in table 11.

FQHCs FQHCs are non-profit, community-directed organizations that offer care to medically underserved patients;

FQHCs are non-profit, community-directed organizations that offer care to medically underserved patients;

FQHCs are the largest primary care system in the United States today.

5 unchanged sentences

Our Quest for Health Equity ® initiative also demonstrates our commitment to FQHCs and the people they serve;

many of these initiatives support FQHCs, including by providing free lab testing services.

Emerging Retail Healthcare Providers In recent years, retail providers of healthcare services have emerged and are growing as customers.

many of these initiatives support FQHCs, including by providing donated testing services.

For more information about our Quest for Health Equity ® initiative, see “ – Our Strengths”.

Hospitals We believe that we are an industry leader in servicing hospitals and serve approximately half the hospitals in the United States each year in many ways.

For more information, see “Our Strategy—Hospitals.”

Patients and Consumers We are well positioned to provide information and insights to patients and individual consumers to help empower them take actions to improve their healthcare.

The changing expectations of patients and individual consumers about their healthcare and their healthcare transactions are influencing our services and the way we provide them.

For more information, see “Our Strategy—Patients and Consumers”.

Factors such as the general economy, the job market and changes in the legal environment (e.g., marijuana legalization or decriminalization) can impact the utilization of drugs-of-abuse testing.

Some employers retain third-party administrators to handle such testing and related services;

we support the needs of third-party administrators as well as employers who retain us directly.

Employers also are investing in population health services.

We meet their needs by providing nationwide access to our customizable services (discussed above), directly and through health plan and health improvement providers.

These services help employers, employees and others manage healthcare costs, capitalize on trends in personalized health and improve health outcomes.

Emerging Retail Healthcare Providers In recent years, we have been seeking the increasing opportunities to provide services to retail providers of healthcare services that have emerged and are growing as customers.

These providers include "big-box" retailers, pharmacy chains, supermarkets, urgent care centers and Internet-based service providers.

We are taking advantage of opportunities to work with these providers, not only to offer new access partners ( e.g ., CVS and Rite-Aid retail locations) and new access points for our services ( e.g ., our collaboration with Safeway), but also to grow our business by expanding our service offerings ( e.g ., our collaboration with Walmart).

See the discussion of our consumer strategy at page 5

Government Agencies We provide services on a fee-for-service basis to federal, state and local governmental agencies.

We are taking advantage of opportunities to work with these providers, not only to offer new access partners (e.g., Rite-Aid retail locations) and new access points for our services (e.g., our collaboration with Safeway), but also to grow our business by expanding our service offerings (e.g., our collaborations with CVS and Walmart).

Pharmaceutical companies We offer clinical trials testing and have expertise with LDTs for companion and complementary diagnostics, and offer an array of assets and services to support the development of companion diagnostics, including our robust data set and patient services network.

We also offer data services solutions, leveraging our data, analytics and expertise, to help therapy developers understand markets and patient and disease journeys, and plan commercial activity.

In addition, we offer Quest Clinical Trials Connect TM to help accelerate clinical trials (and thus the speed of drugs to market) through better patient recruitment, involvement and management, and improved physician outreach.

We also offer Pack Health's patient engagement services.

Other Commercial Clinical Laboratories We also provide services on a fee-for-service basis to other commercial clinical laboratories.

Health Plans, Government Agencies and Other Payers

Most of the services we perform are paid for by commercial payers, including large national health plans, managed care organizations and other health insurance providers, regional and local health plans and government payers, which includes Medicare and Medicaid.

These customers typically reimburse us as a contracted (or out-of-network) provider for services rendered to their members.

In certain locations, health plans may delegate to Independent Physician Associations (“IPAs”) or other alternative delivery systems ( e.g.

, physician organizations, ACOs, patient-centered medical homes) the ability to negotiate for diagnostic information services on behalf of certain members.

Increasingly, these customers are interested in value-based arrangements.

Under capitated payment arrangements, we provide services at a predetermined monthly reimbursement rate for each covered member, generally regardless of the number or cost of services provided by us.

Under some capitated programs, we may provide certain services on a negotiated fee-for-service basis.

Reimbursement under programs that do not provide for capitated payments is typically negotiated on a fee-for-service basis.

Reimbursement from our five largest health plans totaled approximately 20%, and no one health plan accounted for 10%, of our consolidated net revenues in 2023.

Health plans typically negotiate directly or indirectly with a number of diagnostic information services providers, and represent approximately one-half of our total clinical testing volume and > 40% of our net revenues from diagnostic information services.

There has been a trend of consolidation among health plans.

Some health plans also have narrowed their provider networks.

A member of a health plan

may choose to access a non-contracted provider that is a member of a complementary network;

if so, the provider will be reimbursed at a rate negotiated by the complementary network.

We offer to health plans services and programs that leverage our Company's expertise and resources, including our superior patient access, extensive test menu, medical staff, data, IT solutions, and wellness and population health management capabilities.

For the last few years, our Company has had access to a very high percentage of the insured lives in the United States, including very strong access in key high-population states.

We believe that this strong access increases our attractiveness to other customer channels, including physicians, patients and employers.

We also provide services on a fee-for-service basis to federal, state and local governmental agencies.

Historically, most Medicare and Medicaid beneficiaries were covered under the traditional Medicare and Medicaid programs administered by the federal government.

2 unchanged sentences

States also have mandated that Medicaid beneficiaries enroll in private managed care arrangements.

We provide additional services to and in conjunction with government agencies across the United States in connection with the COVID-19 pandemic ( see , e.g ., the discussion at page 10 above regarding our collaboration with CDC).

Pharmaceutical companies We offer clinical trials testing and have expertise with laboratory developed tests for companion and complem entary diagnostics, and offer an array of assets and services to support the development of companion diagnostics, including our robust data set and patient services network.

We also offer data services solutions, leveraging our data, analytics and expertise, to help therapy developers understand markets and patient and disease journeys, and plan commercial activity.

We also offer Pack Health's patient engagement services.

Other Laboratories We provide services on a fee-for-service basis to other commercial clinical laboratories.

While there has been consolidation in the diagnostic information services industry in recent years, our industry remains fragmented and highly competitive.

We also provide additional services to and in conjunction with government agencies across the United States.

For example, in 2023, we formed a novel collaboration with the CDC to research the disease burden of hepatitis C virus in the United States based on our laboratory testing.

While there has been consolidation in the diagnostic information services industry in recent years, which we expect to continue, our industry remains fragmented and highly competitive.

We primarily compete with three types of clinical testing providers:

commercial clinical laboratories, IDN-affiliated laboratories and physician-office laboratories.

other commercial clinical laboratories, including smaller regional and local commercial clinical laboratories and specialized advanced laboratories, hospital-affiliated laboratories and physician-office laboratories.

Our largest commercial clinical laboratory competitor is Laboratory Corporation of America Holdings, Inc.

In addition, we compete with many smaller regional and local commercial clinical laboratories, specialized advanced laboratories and providers of consumer-initiated testing.

We also compete with other providers, including large physician group practices and providers of consumer-initiated testing.

In anatomic pathology, we compete with anatomic pathology practices, including those in academic institutions and large physician group practices, and providers of emerging digital pathology solutions.

There also has been a trend among physician practices to establish their own histology laboratory capabilities and/or bring pathologists into their practices, thereby reducing referrals from these practices and increasing the competitive position of these practices.

Healthcare providers consider a number of factors when selecting a diagnostic information services provider.

Potential Factors Considered When Selecting a Diagnostic Information Services Provider (Table 14)

• Service capability and quality • Reputation in the medical community

• Accuracy, timeliness and consistency in reporting test results

• Healthcare information technology solutions, including connectivity options

• Access to medical/scientific thought leaders for consultation

• Patient access, including the number, convenience and geographic coverage of patient service centers

• Patient insurance coverage and experience • Ability to develop new and useful tests and services

• Number and type of tests performed • Qualifications of its staff

• Pricing and overall value • Provider office workflow

• Real time payment determination • Capabilities to support population health initiatives 0

We believe that providing the most attractive service offering in the industry, including the most comprehensive test menu, innovative test offerings, a positive customer experience, a staff including medical and scientific experts, strong quality, leading access and distribution, and data-powered integrated information technology solutions provide us with a competitive advantage.

We believe that large diagnostic information services providers have a competitive advantage due to their large networks and lower cost structures.

These advantages should enable larger providers to serve customers more effectively.

In addition, we believe that consolidation in the diagnostic information services industry will continue.

However, a significant portion of clinical testing is likely to continue to be performed by IDNs, which generally have affiliations with community clinicians and may have more, or more convenient, locations in a market.

As a result, we compete against IDN-affiliated laboratories primarily on the basis of service capability, quality and pricing.

In addition, market activity may increase the

competitive environment.

For example, IDN ownership of physician practices may enhance the ties of the clinicians to IDN-affiliated laboratories, enhancing the competitive position of IDN-affiliated laboratories.

Some physician practices establish their own histology laboratory capabilities and/or bring pathologists into their practices, thereby reducing referrals from these practices and increasing the competitive position of these practices.

Hospitals generally maintain on-site laboratories to perform testing on their patients (inpatient or outpatient).

In addition, many hospitals compete with commercial clinical laboratories for outreach (non-hospital patients) testing.

Hospitals may seek to leverage their relationships with community clinicians and encourage the clinicians to send their outreach testing to the hospital's laboratory.

As a result of this affiliation between hospitals and community clinicians, we compete against hospital-affiliated laboratories primarily based on quality and scope of service as well as pricing.

In addition, hospitals may have more, or more convenient, locations in a market.

Hospitals that own physician practices may encourage or require the practices to refer testing to the hospital's laboratory.

In recent years, there has been a trend of hospitals acquiring physician practices, increasing the percentage of physician practices owned by hospitals.

Increased hospital ownership of physician practices may enhance clinician ties to hospital-affiliated laboratories and may strengthen their competitive position.

The formation of ACOs and their approach to contracts with healthcare providers also may increase competition to provide diagnostic information services.

In addition, new players have recently started to provide clinical lab testing services ( e.g ., employers;

government agencies) and market activity may continue to increase the competitive environment.

We believe that providing the most attractive service offering in the industry, including the most comprehensive test menu, innovative test offerings, a positive customer experience, a staff including medical and scientific experts, high quality, leading access and distribution, and data-powered integrated IT solutions provide us with a competitive advantage.

We believe that as a large diagnostic information services provider we can serve our customers more effectively due to our larger network and lower cost structure.

In addition, market activity may increase the competitive environment.

The diagnostic information services industry is faced with changing technology, new product introductions and new service offerings.

2 unchanged sentences

Competitors also may compete on the basis of new service offerings.

Competitors also may offer testing to be performed outside of a commercial clinical laboratory, such as (1) point-of-care testing that can be performed by physicians in their offices;

(2) testing that can be performed by IDNs in their own laboratories;

and (3) home testing that can be carried out without requiring the services of outside providers.

The risk assessment and healthcare information technology industries are highly competitive.

Competitors also may offer new testing services that can be performed outside of a commercial

clinical laboratory, such as point-of-care testing that can be administered by physicians in their offices, complex testing that can be performed by hospitals in their own laboratories, and home testing that can be carried out without requiring the services of outside providers.

The risk assessment and healthcare IT industries are highly competitive.

We have many competitors, some of which have much more extensive experience in these industries and some of which have greater resources.

We compete in the risk assessment business by seeking to provide a wider array of quality, integrated services than our competitors, faster services completion and a superior applicant experience.

We compete in the healthcare information technology industry by offering solutions that foster better patient care and improve performance for healthcare providers, particularly smaller and medium sized physician practices.

We compete in the healthcare IT industry by offering solutions that foster better patient care and improve performance for healthcare providers, particularly smaller and medium sized physician practices.

Human Capital Management.

Creating an inspiring workplace is one of our three corporate goals, and this goal drives our approach to human capital management.

Effectively managing our human capital resources is a priority with key components that include culture, safety and well-being programs, employee engagement, and attracting, training, development and succession planning.

Our Board of Directors actively engages in oversight of our human capital management, including by receiving management reports on key areas, strategies and initiatives.

In 2023 we introduced The Quest Way, which has three core components:

why we exist;

our Strategy:

and our Culture:

Our focus on delivering across The Quest Way drives our approach to human capital management.

Effectively managing our human capital resources is a priority with key components that include culture, safety and well-being programs, inclusion, diversity, and employee engagement, and attracting, training, development and succession planning.

Our Board of Directors oversees our human capital management, including by receiving management reports on key areas, strategies, and initiatives.

In 2023, our Board of Directors renamed the Compensation Committee the Compensation and Leadership Development Committee and revised the committee’s charter to include leadership development for senior management other than the Chief Executive Officer, as a committee responsibility.

Additional information about our human capital management strategies and initiatives is available in our annual corporate responsibility report.

8 unchanged sentences

We believe that our overall relations with our employees are good.

We strive to foster a strong culture, built on our Code of Ethics, which reinforces our commitment to integrity and aligns with our vision, values, goals and brand.

Our Quest Management System, discussed above at page 8, supports our effort to maintain a focus on high performance.

We also focus on building and maintaining a collaborative, diverse and inclusive culture in which all employees are empowered to raise and discuss difficult issues and valued for their strengths, experience and unique perspectives (our focus on diversity and inclusion is discussed further below).

We encourage our employees to actively participate in their communities, and support their participation, including offering incentives for participation.

We foster a strong culture, built on our Code of Ethics, which reinforces our commitment to integrity and aligns with our Purpose and brand.

In 2023, we introduced The Quest Way and the 5Cs of Culture —Customer First, Care, Curiosity, Collaboration and Continuous Improvement—to define the behaviors we value and aspire to, every day.

The 5Cs are integrated into our daily management practices, including recognition and performance reviews, to encourage all employees to embody the 5Cs in their daily activities.

Our Quest Management System, supports our effort to maintain a focus on high performance.

We also focus on building and maintaining a collaborative, diverse and inclusive culture in which all employees are empowered to raise and discuss difficult issues and are valued for their strengths, experience and unique perspectives (our focus on diversity and inclusion is discussed further below).

We encourage our employees to actively participate in their communities, and support their participation,through our Employee Business Networks and Matching Gift Program.

Our Everyday Excellence program includes guiding principles for our entire organization to support a superior customer experience and inspire employees to be their best every day, with every person and with every customer interaction;

5 unchanged sentences

We have a comprehensive curriculum of annual safety training, as well as training for new employees.

During the COVID-19 pandemic, our cross-functional Safely Working Together Steering Committee designed and implemented tactics, techniques and procedures to enable our colleagues to continue to work safely.

As part of our comprehensive and competitive compensation and benefits program, we also offer innovative initiatives to support the well-being of our employees and their families through our HealthyQuest™ program.

The cornerstone of HealthyQuest is our Blueprint for Wellness program, which empowers our employees and their dependents with health insights based on lab and biometric data and invites them each year to take the initiative to improve their physical and mental health.

We also offer other programs designed to engage employees in managing their health, including access to medical expertise and support programs tailored to their individual needs, helping them to adopt healthier behaviors and access better care at lower costs.

These include customized programs for conditions such as type 2 diabetes management, chronic kidney disease, cardiovascular disease, specialty drugs, and zero-cost lab testing, and

special support for orthopedic surgery and for cancer and other serious diagnoses.

In 2022, we enhanced our mental health offering for employees.

The cornerstone of HealthyQuest™ is our Blueprint for Wellness ® program, which empowers our employees and their spouses and partners with health insights based on lab and biometric data and invites them each year to take the initiative to improve their physical and mental health.

We also offer comprehensive medical and mental health plans.

For example, our mental health support service, launched in 2022, continues to be widely used among our employees and their dependents.

HealthyQuest™ focuses on prevention, progression

and reversal, through which we offer a HealthyQuest™ Employee Business Network and intervention programs designed to engage employees in managing their health, including access to medical expertise and support programs tailored to their individual needs, helping them to adopt healthier behaviors and access better care at lower costs.

These programs include customized programs for conditions such as type 2 diabetes management, chronic kidney disease, cardiovascular disease, specialty drugs, and zero-cost lab testing, and special support for orthopedic surgery and for cancer and other serious diagnoses.

Inclusion and Diversity .

1 unchanged sentence

We aim to harness the unique mix of capabilities, talents, cultures, beliefs and experience of our employees and create a workforce that is demographically diverse at all levels of the organization.

Through our CTC Framework (focusing on Culture, Talent and Community), we prioritize diversity across the entire talent lifecycle, with the goals of supporting employees throughout their careers at Quest, ensuring transparency and identifying opportunities for action.

In 2022, we continued to focus on inclusion and diversity through additional training for leaders and other employees.

Through our focus on Culture, Talent and Community, we prioritize diversity across the entire talent lifecycle, with the goals of supporting employees throughout their careers at Quest, ensuring transparency and identifying opportunities for action.

In 2023, we expanded our focus on inclusion and diversity through leadership training programs like McKinsey Connected Leaders Academy, Franklin Covey’s Leading at the Speed of Trust, and a Mentoring Circles program focused on developing inclusive leadership competencies in front line supervisors.

Additionally, we launched an Everyday Equity Council comprised of diverse leaders from our Employee Business Networks to offer regular feedback to organizational leaders on opportunities to further enhance inclusivity of programs, policies, and services.

Our employee engagement on Inclusion and Diversity was also evidenced by the approximately 60% growth in Employee Business Network membership in 2023.

We also continued, with the Quest Diagnostics Foundation, Quest for Health Equity ® , our initiative to help reduce health disparities in underserved communities.

Since 1997, we have sought to foster the engagement and enablement of our employees, and have regularly surveyed our employees to assess their engagement.

For more information about our Quest for Health Equity ® initiative, see "-Our Strengths".

Actively listening to our employees is fundamental to Quest’s culture.

We have always sought to foster the engagement of our employees and take action to improve the employee experience, through the use of regular employee insight surveys.

Employee engagement has been a metric in the annual incentive plan for our executive officers since 2013.

Since 2020, our strategy for gathering employee feedback utilizes more frequent employee surveys.

Since 2020, our strategy for gathering employee feedback utilizes more frequent employee insight surveys.

This approach is designed to build an agile culture, based on continuous feedback that fuels ongoing conversations about priorities, performance, opportunities and growth, to result in a higher performing organization and committed employees.

To gain deeper insights from our employees, we expanded our effort across the employee lifecycle, to gain the unique feedback of our new hires, newly acquired team members, and our departing colleagues.

In addition, we hold regular meetings among hundreds of company leaders to foster increased communication across the company regarding topics of concern to employees.

1 unchanged sentence

We have a strong program designed to attract a diverse, qualified work force that will assist us to achieve our business goals.

For example, we are partnering with universities to help build our pipeline of expertise in medical technology, cytology and histology, and we have teamed up with a third-party phlebotomy training program to train and certify phlebotomist candidates who can join our ranks upon graduation.

For example, we are partnering with universities and specialized healthcare schools to help build our pipeline of expertise in medical technology, cytology and histology, and we have teamed up with a third-party phlebotomy training program to train and certify phlebotomist candidates who can join our ranks upon graduation.

In addition, we post all our jobs on a number of sites that specifically attract diverse talent.

We provide training on a wide array of topics to our employees through live and online formats, including opportunities that can be accessed through their mobile devices.

We also offer a number of development opportunities for our employees, such as mentoring and education programs, including a higher education tuition assistance program.

In addition, we provide leadership training opportunities for employees at all levels, including a manager essentials curriculum, our Leading Quest Supervisor and Manager Core Program, coaching programs and trainings to strengthen critical leadership skills.

We also offer a number of development opportunities for our employees through a robust library of offerings in our Learning Management System, EMPower.

We also facilitate mentoring and education programs and a higher education tuition assistance program, My Quest for Education.

In addition, we provide leadership training opportunities for employees at all levels, including a manager essentials curriculum, our Leading Quest Supervisor and Manager Core Program, our director-level Leading Quest for Business Impact program, coaching programs and trainings to strengthen critical leadership skills.

We also deliver a number of programs tailored to specific functions to drive a high-performance culture and sharpen the capabilities needed to lead our organization ( e.g ., our Commercial, Finance, Pathology, R&D, and Product Management Leadership Programs).

We have a robust talent assessment and succession planning process to promote business continuity, including at the most senior levels;

this planning is linked to our engagement and inclusion and diversity initiatives, to foster those efforts.

Quest’s robust talent review and succession planning process assesses current and future organizational needs in combination with the capabilities and aspirations of our employees to ensure we have the right talent, in the right roles, at the right time.

For leaders, we have robust succession plans and leverage several inputs, inclusive of formal assessments, to inform customized development plans.

Sales and Marketing.

Our Diagnostic Information Services business has a unified commercial organization focused on the sale of most of our services.

It coordinates closely with our clinical franchises (discussed above under the heading I nnovation ) and marketing organization.

It coordinates closely with our clinical franchises (discussed above under the heading "Organized to Drive Growth and Value") and marketing organization.

The commercial organization is centrally led, and is organized regionally, in conjunction with our operations organization, to focus on local customer needs and to ensure aligned delivery for our customers.

Our commercial organization employs world-class processes and tools and strong management discipline.

We provide industry-leading training and development, focus on opportunities with IDNs and specialty physicians, and foster a customer-focused, performance-driven culture.

We also maintain distinct sales and marketing organizations for our offerings in Diagnostic Solutions and our employer drugs-of-abuse testing services.

Our commercial organization employs leading processes and tools and strong management discipline.

We provide industry-leading training and development, focus on opportunities with hospitals and specialty physicians, and foster a customer-focused, performance-driven culture.

We also maintain distinct sales and marketing organizations for our offerings in Diagnostic Solutions and our employer testing services.

Information Technology.

2 unchanged sentences

The successful delivery of our services depends, in part, on the continued and uninterrupted performance of our information technology systems.

We take precautionary measures to prevent problems that could affect our information technology systems.

We take precautionary measures to prevent problems that could affect our IT systems.

Some of our historic growth has come through acquisitions and, as a result, we continue to use multiple information systems.

3 unchanged sentences

Quality Assurance.

As discussed further under the heading Quality on page 8, our goal is to provide every patient with services and products of superior quality, and to meet that goal we employ the Quest Management System.

As discussed further under the heading "Continuous Quality Improvement", our goal is to provide every patient with services and products of superior quality, and to meet that goal we employ the Quest Management System.

Employing root cause analysis, process improvements and rigorous tracking and measuring, we continuously seek to enhance quality, reduce defects, further increase the efficacy and efficiency of our operations and processes, eliminate waste and help standardize operations across our Company.

5 unchanged sentences

For example, our cytotechnologists and pathologists participate in an internal peer-review evaluation and one or more external individual proficiency testing programs.

We have accreditation or licenses for our clinical laboratory operations from various regulatory agencies or accrediting organizations, such as CMS, CAP and certain states.

We have accreditation or licenses for our clinical laboratory operations from various regulatory agencies or accrediting organizations, such as CMS, The College of American Pathologists (“CAP”) and certain states.

All of our laboratories participate in external quality surveillance programs, including proficiency testing programs administered by CAP and several state agencies.

CAP is an independent, nongovernmental organization of board-certified pathologists approved by CMS to inspect clinical laboratories to determine compliance with the standards required by CLIA.

CAP is an independent, nongovernmental organization of board-certified pathologists approved by CMS to inspect clinical laboratories to determine compliance with the standards required by the Clinical Laboratory Improvement Act (“CLIA”).

CAP offers an accreditation program to which clinical laboratories may voluntarily subscribe.

All of our major laboratories, including our laboratories outside the U.S., and a number of our rapid response laboratories, are accredited by CAP.

All of our major laboratories, including our laboratories outside the United States, and a number of our rapid response laboratories, are accredited by CAP.

Accreditation includes on-site inspections and participation in the CAP (or equivalent) proficiency testing program.

In addition, some of our laboratories also have International Organization for Standardization (ISO) certification for their quality management systems.

For example, in 2022, we achieved ISO 14001 certification for our esoteric laboratory facility at San Juan Capistrano, CA.

ISO 14001 is an internationally recognized management system that leverages leadership involvement and employee engagement to help organizations ensure compliance with regulatory standards, improve their environmental performance, provide a competitive advantage and gain the trust of stakeholders, and achieve strategic goals by incorporating environmental issues into business management.

We maintain a robust Supplier Quality Program designed to ensure a high-quality supplier network and to raise the bar of quality expectation across that network.

3 unchanged sentences

In choosing suppliers, we evaluate their quality systems and quality performance metrics.

Our supplier qualification process is risk-based, with assessments and on-site audits based on risk tiers.

Our supplier qualification process is risk-based, with assessments and on-site audits based on risk tiers and supplier quality management system compliance.

Contracts with our suppliers include specific quality, compliance, and change management provisions as appropriate.

We use supplier quality engineers who are trained to audit on ISO standards and FDA regulations applicable to suppliers’ processes, and a procurement engineering team to assist with qualification and validation of new supplies and products.

We actively manage supplier performance, utilizing a problem reporting and resolution process designed to drive to root cause and corrective actions.

We actively manage supplier performance, utilizing a problem reporting and resolution process designed to drive to root cause and

corrective actions.

We maintain a continuous improvement dialogue with our suppliers, and with operationally critical suppliers deliver a supplier scorecard that supports continuous improvement.

We also maintain quality assurance programs for IDN laboratories that we manage, and for our services offerings outside laboratories.

We also maintain quality assurance programs for hospital laboratories that we manage, and for our services offerings outside laboratories.

Intellectual Property Rights.

7 unchanged sentences

Enterprise Risk Management Program .

We maintain an enterprise risk management program designed to promote a culture of risk awareness throughout the Company's key business, operations and support functions.

We maintain an enterprise risk management program, which is led by our executive leadership and overseen by our Board of Directors, that is designed to promote a culture of risk awareness throughout the Company's key business, operations and support functions.

Our program, which is integrated with the Company’s governance, performance management and internal control frameworks, entails a formal continuous process that identifies, assesses, mitigates and manages the risks from both internal and external conditions that could significantly impact the Company and influence its business strategy and performance, including environmental, social and governance issues.

The program is designed based on the most recent framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, and we benchmark it against best practices.

The program, which is managed by an enterprise risk management team, is designed based on the most recent framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, and we benchmark it against best practices.

We focus on the following risk types:

7 unchanged sentences

• Legal and compliance risk - risks arising from the regulatory and enforcement environment, legal proceedings and adherence to ethics and compliance policies and procedures.

• Strategic risk - risks that will impede the Company’s plan to achieve its mission and vision and apply its core values, including changes in the broad market and Company's industry, business development and restructuring activities, competitive threats and practices, technology and product innovation, and public policy.

As part of our program, we routinely assess our enterprise level risks, emerging risks, overall Company-level risk tolerance and the effectiveness of risk management, and monitor the progress of and resources applied to risk mitigation;

our Board of Directors actively oversees our program.

Our primary risk factors are discussed in Risk Factors beginning on page 32 .

• Strategic risk - risks that will impede the Company’s plan to achieve its Purpose and apply its core values, including changes in the broad market and Company's industry, business development and restructuring activities, competitive threats and practices, technology and product innovation, and public policy.

As part of our program, together with our Board of Directors, we routinely assess our enterprise level risks, emerging risks, overall Company-level risk tolerance and the effectiveness of risk management, and monitor the progress of and resources applied to risk mitigation.

Our Board of Directors and its committees receive updates and training from internal and external experts on topics that are relevant to overall risk management.

Our primary risk factors are discussed in "Risk Factors" below.

Government Reimbursement.

2 unchanged sentences

The types of fee schedules are:

• “Client” fees charged to physicians, IDNs and institutions for which services are performed on a wholesale basis and which are billed on a monthly basis.

• “Client” fees charged to physicians, hospitals and institutions for which services are performed on a wholesale basis and which are billed on a monthly basis.

• “Patient” fees charged to individual patients and certain third-party payers on a claim-by-claim basis.

Billing for diagnostic information services is very complicated.

Our customers, discussed in table 13, have different billing requirements.

Our customers have different billing requirements.

Some billing arrangements require us to bill multiple payers, and there are several other factors that complicate billing ( e.g ., disparity in coverage and information requirements among payers;

7 unchanged sentences

Historically, the Medicare Clinical Laboratory Fee Schedule and the Medicare Physician Fee Schedule established under that program have been subject to change, including each year.

Pursuant to PAMA, reimbursement rates for many clinical laboratory tests provided under Medicare were reduced from 2018 - 2020.

PAMA calls for further revision of the Medicare Clinical Laboratory Fee Schedule for years after 2020, based on future surveys of market rates;

reimbursement reduction from 2024-26 is capped by PAMA at 15% annually.

Our net revenues reimbursed under Medicare and Medicaid in 2022 were lower as a percentage of our consolidated net revenues than in recent years (excluding 2021 and 2020, when we also experienced significant COVID-19 testing).

Excluding revenues attributable to COVID-19 testing, approximately 12% of our net revenues were reimbursed under Medicare and Medicaid in 2022, compared to approximately 15% in 2019.

Pursuant to PAMA, reimbursement rates for many clinical laboratory tests provided under Medicare were reduced during 2018 - 2020.

Unfortunately, as a result of a flawed implementation of PAMA, the data collected did not accurately represent the laboratory market as required under PAMA.

PAMA calls for further revision of the Medicare CLFS for years after 2020, based on future surveys of market rates.

reimbursement rate reduction from 2025-27 is capped by PAMA at 15% annually.

Congress reintroduced federal legislation in 2023 (the Saving Access to Laboratory Services Act), which, if enacted, would reform PAMA and create a true market-based CLFS.

We are subject to extensive and frequently changing laws and regulations in the United States (at both the federal and state levels) and other jurisdictions in which we conduct business, and to government inspections and audits.

Key Regulatory Schemes (Table 16)

Key Regulatory Schemes

CLIA and State Clinical Laboratory Licensing CLIA regulates the operations of virtually all clinical laboratories, requiring that they be certified by the federal government and that they comply with various technical, operational, personnel and quality requirements intended to ensure that the services provided are accurate, reliable and timely.

11 unchanged sentences

The FDA has claimed regulatory authority over all LDTs, but has stated that it exercised enforcement discretion with regard to most LDTs performed by high complexity CLIA-certified laboratories.

Pursuant to the 21st Century Cures Act, the FDA issued final guidance regarding its position on the regulation of clinical decision software, which may be used in connection with LDTs.

The guidance attempts to address uncertainty regarding whether FDA approval of certain software is required.

It has been used by the FDA, in part, to assert authority over the annotation software aspects of pharmacogenetic testing services.

The FDA and HHS have expressed views regarding the regulation of LDTs.

Legislation introduced in recent sessions of Congress that would authorize the FDA to regulate LDTs has not become law.

The FDA and HHS have expressed views regarding the regulation of LDTs including the FDA’s jurisdiction over them.

Previously proposed legislation introduced in Congress that would have authorized the FDA to regulate LDTs has not become law.

In October 2023, the FDA announced a proposed rule that would broaden the definition of medical device to include diagnostic tests and laboratories that develop them.

Publication of a final rule initiates a four-year period for a staged process of compliance and submissions.

The proposed rule could also impact a revitalization and passage of legislation that authorizes the FDA to regulate LDTs by amending the Food, Drug and Cosmetic Act.

New competitors may enter the industry, and competition may come in new forms.

1 unchanged sentence

For example, the U.S.

Occupational Safety and Health Administration has established extensive requirements relating specifically to workplace safety for healthcare employers in the U.S.

This includes requirements to develop and implement multi-faceted programs to protect workers from exposure to blood-borne pathogens, including preventing or minimizing any exposure through needle stick injuries.

Occupational Safety and Health Administration has established extensive requirements relating specifically to workplace safety for healthcare employers in the United States This includes requirements to develop and implement multi-faceted programs to protect workers from exposure to blood-borne pathogens, including preventing or minimizing any exposure through needle stick injuries.

For purposes of transportation, some biological materials and laboratory supplies are classified as hazardous materials and are subject to regulation by one or more of the following agencies:

6 unchanged sentences

In these jurisdictions, anatomic pathology services are delivered through physician-owned entities that employ the practicing pathologists.

Privacy and Security of Health and Personal Information We are subject to laws and regulations regarding protecting the security and privacy of certain healthcare and personal information, including:

Privacy and Security of Health and Personal Information We are subject to laws and regulations regarding protecting the security and privacy of certain healthcare and personal information, including, but not limited to:

(a) the federal Health Insurance Portability and Accountability Act and the regulations thereunder, which establish (i) a complex regulatory framework including requirements for safeguarding protected health information and (ii) comprehensive federal standards regarding the uses and disclosures of protected health information;

23 unchanged sentences

www.QuestDiagnostics.com/investor provides information about our corporate governance.

Information Available at Our Corporate Governance Webpage (Table 17)

Information Available at Our Corporate Governance Webpage

• Corporate Governance Guidelines

8 unchanged sentences

www.QuestDiagnostics.com/our-company/corporate-responsibility provides information about our corporate responsibility program.

Information Available at Our Corporate Responsibility Webpage (Table 18)

Information Available at Our Corporate Responsibility Webpage

• Corporate Responsibility Reports

7 unchanged sentences

INFORMATION ABOUT OUR EXECUTIVE OFFICERS

Executive Officers (Table 19)

Executive Officers

Name, Age, Title Background

Chief Executive Officer and President On November 1, 2022, Mr.

Chairman, Chief Executive Officer and President On November 1, 2022, Mr.

Davis became Chief Executive Officer and President, having served as CEO-Elect since February 3, 2022.

5 unchanged sentences

From February 2014 to January 2015, he was responsible for operations for the Company's Diagnostic Information Services business.

Davis joined Quest Diagnostics in April 2013 as Senior Vice President, Diagnostics Solutions, with responsibility for the healthcare information technology, risk assessment, clinical trials, diagnostic products and employer solutions businesses.

Davis joined Quest Diagnostics in April 2013 as Senior Vice President, Diagnostics Solutions, with responsibility for the healthcare IT, risk assessment, clinical trials, diagnostic products and employer solutions businesses.

Prior to joining Quest Diagnostics, from March 2012 to April 2013, Mr.

12 unchanged sentences

Previously, Mr.

Delaney served in a number of senior sales and marketing leadership roles at General Electric's healthcare business, most recently as Senior Vice President and Zone Manager, where he had regional responsibility for sales of imaging, patient monitoring, information technology and services.

Senior Vice President, Regional Businesses Since March 2022, Ms.

Doherty has been responsible for the general management of the Company's regional Diagnostic Information Services business, the commercial organization, marketing and consumer-initiated testing.

Doherty has been responsible for the general management of the Company's regional Diagnostic Information Services business, the commercial organization and marketing.

She also is responsible for driving operational excellence, including the Company's quality and efficiency initiatives.

Doherty is the Executive Sponsor of the Company's Women in Leadership Employee Business Network.

Doherty is the Executive Sponsor of the Company's Women in Leadership Employee Business Network and was formerly co-chair of the Company's Inclusion and Diversity Council.

From January 2020 to January 2023, she was responsible for consumer-initiated testing, which was launched under her leadership.

From January 2013 to March 2022, Ms.

Doherty was Senior Vice President and Group Executive - Clinical Franchise Solutions and Marketing.

In this role, she was responsible for overseeing the development of clinical franchise solutions in the areas of general health and wellness, cardiovascular, metabolic and endocrinology, infectious disease and immunology, and prescription drug monitoring and toxicology, as well as enterprise-wide marketing, consumer-initiated testing, the employer solutions and risk assessment businesses, and beginning in February 2020, our sports diagnostics franchise.

She also was responsible for clinical franchise solutions in the areas of neurology and women's health from January 2013 to January 2017 and for the healthcare information technology business from February 2014 to January 2017.

In this role, she was responsible for overseeing the development of clinical franchise solutions in the areas of general health and wellness, cardiovascular, metabolic and endocrinology, infectious disease and immunology, and prescription drug monitoring and toxicology, as well as enterprise-wide marketing, the employer solutions and risk assessment businesses, and beginning in February 2020, our sports diagnostics franchise.

She also was responsible for clinical franchise solutions in the areas of neurology and women's health from January 2013 to January 2017 and for the healthcare IT business from February 2014 to January 2017.

Prior to January 2013, Ms.

9 unchanged sentences

Gardner joined Quest from Corza Medical, a provider of surgical technologies and tools, where he served since 2019 as Executive Partner, Senior Vice President and General manager of European Commercial Operations and Biosurgery Products.

Prior to that, Mr.Gardner served as Chief Executive Officer of OmniSeq Corporation, a molecular diagnostics company, from 2016 to 2019 and in Vice President and General Manager positions at Thermo Fisher Scientific Inc.

Prior to that, Mr.

Gardner served as Chief Executive Officer of OmniSeq Corporation, a molecular diagnostics company, from 2016 to 2019 and in Vice President and General Manager positions at Thermo Fisher Scientific Inc.

from 2003 to 2016, including roles with Life Technologies and Invitrogen.

3 unchanged sentences

Kuppusamy assumed his current role in August 2022.

He is responsible for the Company's clinical franchises other than oncology, as well as the Company's pharmaceutical services, genomic services, medical affairs, medical quality and global markets activities.

He is responsible for the following clinical franchises:

Cardiovascular, Metabolic, Endocrinology and Wellness, Drug Monitoring and Toxicology, Infectious Disease and Immunology, Neurology, and Women’s and Reproductive Health.

He is also responsible for the Company's pharmaceutical services, genomic customer services, medical affairs, medical quality and regulatory.

Kuppusamy serves as co-chair of the Company's Inclusion and Diversity Council.

11 unchanged sentences

Previously, Mr.

Plewman held various positions of increasing responsibility at SmithKline Beecham Inc.

Plewman held various positions of increasing responsibility at SmithKline Beecham.

Prevoznik (62)

5 unchanged sentences

Prevoznik also had responsibility for the Company's Compliance Department.

In addition, from April 2011 to January 2017, he had management responsibility for the Company's diagnostic information services activities outside the U.S., and from April 2011 to January 2013, he had management responsibility for the Company's clinical trials business.

In addition, from April 2011 to January 2017, he had management responsibility for the Company's diagnostic information services activities outside the United States, and from April 2011 to January 2013, he had management responsibility for the Company's clinical trials business.

Prior to joining the Company, Mr.

8 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business